Human interleukin-4 receptor alpha antibody glucocorticoid conjugate

Novel IL-4Rα antibody-GC conjugates address the limitations of current treatments by inhibiting IL-4 and IL-13 signaling and modulating glucocorticoid receptor responses, offering a stable and effective treatment for various inflammatory diseases.

JP7595195B2Active Publication Date: 2024-12-05ELI LILLY & CO
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023577245
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-06-02
Filing Date
2023-05-31
Publication Date
2024-12-05
Estimated Expiration
2043-05-31

AI Technical Summary

Technical Problem

Current treatments for inflammatory diseases such as atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic diseases, chronic obstructive pulmonary disease, and chronic spontaneous urticaria are limited by the disadvantages of existing therapies, necessitating the development of new compounds that effectively target interleukin-4 receptor alpha (IL-4Rα) to modulate immune responses.

Method used

Development of novel human IL-4Rα antibody-glucocorticoid receptor agonist (GC) conjugates that bind to IL-4Rα, inhibiting IL-4 and IL-13 signaling, modulating glucocorticoid receptor responses, and reducing inflammation, while maintaining stability and bioavailability for therapeutic use.

Benefits of technology

The conjugates effectively inhibit IL-4 and IL-13 signaling, reduce inflammation, and demonstrate improved stability and solubility, providing a promising treatment for type 2 inflammatory diseases with reduced adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595195000090
    Figure 0007595195000090
  • Figure 0007595195000091
    Figure 0007595195000091
  • Figure 0007595195000092
    Figure 0007595195000092
Patent Text Reader

Abstract

The present disclosure provides human interleukin-4 receptor alpha antibody-glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure provides a human interleukin-4 receptor alpha antibody glucocorticoid receptor agonist conjugate, a method of using the conjugate for the treatment of an inflammatory disease, e.g., a type 2 inflammatory disease, such as atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic disease, chronic obstructive pulmonary disease, or chronic spontaneous urticaria, a process for preparing the conjugate, and a pharmaceutical composition comprising the conjugate. [Background technology]

[0002] Atopic dermatitis is a chronic, pruritic, relapsing and remitting inflammatory skin disease that occurs frequently in children but also affects many adults. Current treatments for atopic dermatitis include phototherapy, topical creams containing corticosteroids or calcineurin inhibitors, or a subcutaneously injectable biologic known as dupilumab. Despite the progress made in the treatment of atopic dermatitis, there is a significant need for new compounds that minimize or eliminate the disadvantages of currently approved treatments for treating atopic dermatitis and other inflammatory and autoimmune diseases.

[0003] WO 2017 / 210471 discloses certain glucocorticoid receptor agonists (GCs) and immunoconjugates thereof useful for treating inflammatory diseases. WO 2018 / 089373 discloses novel steroids, protein conjugates thereof, and methods for treating diseases, disorders, and conditions comprising administering the steroids and conjugates. To date, no human IL-4Rα GC conjugates are known for the treatment of developing inflammatory diseases. Summary of the Invention

[0004] The present disclosure provides certain novel human IL-4Rα antibody GC conjugates, in which the antibody binds to human IL-4Rα. The present disclosure further provides compositions comprising the novel anti-human IL-4Rα antibody GC conjugates, as well as methods of using such anti-human IL-4Rα antibody GC conjugates and compositions thereof. The present disclosure further provides certain novel anti-human IL-4Rα GC conjugates useful in the treatment of inflammatory diseases, such as atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic diseases, chronic obstructive pulmonary disease, or type 2 inflammatory diseases, such as chronic spontaneous urticaria.

[0005] Certain anti-human IL-4Rα antibody GC conjugates provided herein have one or more of the following properties: 1) bind to a novel epitope spanning the N-terminal fibronectin type III domains 1 and 2 of human and / or cynomolgus monkey IL-4Rα; 2) bind to human IL-4Rα with a desired binding affinity; 3) bind to cynomolgus monkey IL-4Rα with a desired binding affinity; 4) bind to human IL-4Rα on the cell surface and are internalized into the cell; 5) bind to human IL-4Rα and inhibit binding of IL-4 and IL-13 to IL-4Rα; 6) bind to IL-4Rα and inhibit IL-4R-mediated responses in vitro (pSTAT6, B cell proliferation, CD23 expression, cytokine production (e.g., MDC, GM-CSF) in B cells and T cells); 7) bind to human and / or cynomolgus monkey IL-4Rα with a desired binding affinity; and / or cynomolgus IL-4Rα; 8) modulate glucocorticoid receptor agonist-mediated responses in vitro (induce CD163 expression, inhibit B cell proliferation, inhibit cytokine production (e.g., IL-5, GM-CSF)); 9) modulate glucocorticoid receptor agonist-mediated gene expression (upregulate: Tsc22d3, Fkbp5, Zbtb16; downregulate: IL-5); 10) do not significantly induce ADCC or CDC activity; 11) retain Fcγ receptor binding to B cells and / or myeloid cells; 12) inhibit inflammatory responses in vivo; or 13) have a good developability profile, e.g., acceptable viscosity, solubility, and aggregation stability for ease of development, manufacturing, and / or formulation.

[0006] Thus, in one embodiment, the present disclosure provides a compound of formula I: [ka] where Ab is an antibody that binds to human interleukin-4 receptor alpha ("anti-human IL-4Rα antibody"); [ka] and n is 1 to 5.

[0007] In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, F41, L42, L43, E45, H47, T48, C49, I50, E52, H62, L64, M65, D66, D67, V68, V69, D72, R99, P121, P123, P124, D125, P192 (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises at least one, at least two, at least three, at least four, or at least five or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, F41, L42, L43, E45, H47, T48, C49, I50, E52, H62, L64, M65, D66, D67, V68, V69, D72, R99, P121, P123, P124, D125, P192 (positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from D12, M14, S15, I16, L39, F41, L42, T48, C49, I50, E52, H62, L64, M65, D66, D67, V68, V69, D72, R99, P121, P123, P124, D125, P192 (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises at least one, at least two, at least three, at least four, at least five or more amino acid residues selected from D12, M14, S15, I16, L39, F41, L42, T48, C49, I50, E52, H62, L64, M65, D66, D67, V68, V69, D72, R99, P121, P123, P124, D125, P192 (positions of the amino acid residues correspond to SEQ ID NO: 15).In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, F41, L43, E45, H47, T48, C49, I50, H62, L64, M65, D66, D67, V69, D72, R99, P121, P123, P124, D125 (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises at least one, at least two, at least three, at least four, at least five or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, F41, L43, E45, H47, T48, C49, I50, H62, L64, M65, D66, D67, V69, D72, R99, P121, P123, P124, D125 (positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, T48, C49, I50, E52, H62, M65, R99, P121, P123, P124, D125, P192 (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, wherein the epitope comprises at least one, at least two, at least three, at least four, at least five or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, T48, C49, I50, E52, H62, M65, R99, P121, P123, P124, D125, P192 (positions of the amino acid residues correspond to SEQ ID NO: 15).In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, the epitope comprising one or more amino acid residues selected from R99, P121, P123, P124, D125, P192 (the amino acid residue positions correspond to SEQ ID NO: 15), which are located in domain 2 of the N-terminal fibronectin type III domain of IL-4Rα. In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, the epitope comprising one or more amino acid residues selected from D66, D67, and D125 (the amino acid residue positions correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, the epitope comprising at least one of the amino acid residues selected from D66 and D67 (the amino acid residue positions correspond to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, the epitope comprising at least one of the amino acid residues selected from D66 and D125 (the amino acid residue position corresponds to SEQ ID NO: 15). In some embodiments, the Ab in the conjugate of formula I binds to an epitope of human IL-4Rα, the epitope comprising amino acid residue D66 (the amino acid residue position corresponds to SEQ ID NO: 15). In yet other embodiments, the Ab in the conjugate of formula I binds to a novel structural and / or functional epitope of human IL-4Rα, the epitope spanning domain 1 and domain 2 of the N-terminal fibronectin type III domain of IL-4Rα. In certain embodiments, the Ab in the conjugate of formula I binds to a novel structural and / or functional epitope of human IL-4Rα, the epitope overlapping with the IL-4 binding site for IL-4Rα. In such embodiments, the Ab in the conjugate of Formula I blocks binding of IL-4 to human IL-4Rα. In certain embodiments, the Ab in the conjugate of Formula I binds to a novel structural and / or functional epitope of human IL-4Rα, which epitope overlaps with the IL-13 binding site for IL-4Rα.In such embodiments, the Ab in the conjugate of formula I blocks the binding of IL-13 to human IL-4Rα. In certain embodiments, the Ab in the conjugate of formula I binds to a novel structural and / or functional epitope of human IL-4Rα, which epitope overlaps with both the IL-4 binding site and the IL-13 binding site on IL-4Rα. In such embodiments, the Ab in the conjugate of formula I blocks the binding of IL-4 and IL-13 to human IL-4Rα. In some embodiments, in the conjugate of formula I, the IL-4Rα epitope is determined by X-ray crystallography, alanine scanning mutagenesis, steric hindrance mutagenesis, and / or HDX-MS. In yet other embodiments, the IL-4Rα epitope is determined by site-directed mutagenesis.

[0008] In a further embodiment, the present disclosure provides a compound of formula I: [ka] wherein Ab is an antibody that binds to the human interleukin-4 receptor alpha ("anti-human IL-4Rα antibody"), the Ab comprising a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0009] In a further embodiment, the present disclosure provides a compound of formula Ia: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0010] In a further embodiment, the present disclosure provides a compound of formula Ib: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0011] In a further embodiment, the present disclosure provides a compound of formula Ic: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0012] In a further embodiment, the present disclosure provides a compound of formula Id: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0013] In a further embodiment, the present disclosure provides a compound of formula Ie: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0014] In a further embodiment, the present disclosure provides a compound of formula If: [ka] (wherein Ab is an antibody that binds to human IL-4Rα, Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; HCDR1 comprises SEQ ID NO: 1, 19 or 42; HCDR2 comprises SEQ ID NO: 2 or 20, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO: 4 or 22; LCDR2 comprises SEQ ID NO:5, LCDR3 comprises SEQ ID NO: 6 or 24; [ka] and n is 1 to 5.

[0015] In one embodiment, n is 2-5.

[0016] In one embodiment, n is 3-5.

[0017] In one embodiment, n is 3-4.

[0018] In one embodiment, n is about 4.

[0019] In one embodiment, n is about 3.

[0020] In one embodiment, n is about 2.

[0021] In some embodiments, the Ab comprises a VH and a VL, where the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, where HCDR1 comprises SEQ ID NO:1, HCDR2 comprises SEQ ID NO:2, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO:4, LCDR2 comprises SEQ ID NO:5, and LCDR3 comprises SEQ ID NO:6. In some embodiments, the Ab comprises a VH comprising SEQ ID NO:7, and a VL comprising SEQ ID NO:8. In some embodiments, the Ab is Ab1, where Ab1 comprises a HC comprising SEQ ID NO:9, and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab2, where Ab2 comprises a HC comprising SEQ ID NO:50, and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab3, where Ab3 comprises a HC comprising SEQ ID NO:37, and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab4, where Ab4 comprises a HC comprising SEQ ID NO:31 and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab5, where Ab5 comprises a HC comprising SEQ ID NO:35 and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab6, where Ab6 comprises a HC comprising SEQ ID NO:33 and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab7, where Ab7 comprises a HC comprising SEQ ID NO:13 and a LC comprising SEQ ID NO:10. In some embodiments, the Ab is Ab8, where Ab8 comprises a HC comprising SEQ ID NO:52 and a LC comprising SEQ ID NO:10.

[0022] In some embodiments, the Ab comprises a VH and a VL, wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein HCDR1 comprises SEQ ID NO:42, HCDR2 comprises SEQ ID NO:2, HCDR3 comprises SEQ ID NO:3, LCDR1 comprises SEQ ID NO:22, LCDR2 comprises SEQ ID NO:5, and LCDR3 comprises SEQ ID NO:6. In some embodiments, the Ab comprises a VH comprising SEQ ID NO:44 and a VL comprising SEQ ID NO:45. In some embodiments, the Ab is Ab9, wherein Ab9 comprises a HC comprising SEQ ID NO:46 and a LC comprising SEQ ID NO:47.

[0023] In some embodiments, the Ab comprises a VH and a VL, wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein HCDR1 comprises SEQ ID NO: 19, HCDR2 comprises SEQ ID NO: 20, HCDR3 comprises SEQ ID NO: 3, LCDR1 comprises SEQ ID NO: 22, LCDR2 comprises SEQ ID NO: 5, and LCDR3 comprises SEQ ID NO: 24. In some embodiments, the Ab comprises a VH comprising SEQ ID NO: 25, and a VL comprising SEQ ID NO: 26. In some embodiments, the Ab is Ab10, wherein Ab10 comprises a HC comprising SEQ ID NO: 27, and a LC comprising SEQ ID NO: 28.

[0024] In some embodiments, the Ab in the conjugate of formula I binds to human IL-4Rα and inhibits binding of human IL-4 and human IL-13 to human IL-4Rα. In some embodiments, the Ab in the conjugate of formula I binds to human IL-4Rα and inhibits IL-4R receptor-mediated responses (e.g., inhibits pSTAT6 in B and T cells, inhibits B cell proliferation, inhibits CD23 expression, inhibits cytokine secretion (e.g., MDC, GM-CSF)). In some embodiments, the Ab in the conjugate of formula I binds to human IL-4Rα and does not significantly induce ADCC or CDC activity. In some embodiments, the Ab in the conjugate of formula I binds to human IL-4Rα on the cell surface and internalizes the conjugate of formula I into the cell.

[0025] In some embodiments of the present disclosure, the Ab in the conjugate of formula I is a fully human antibody. In some embodiments of the present disclosure, the Ab in the conjugate of formula I has a human IgG4 or human IgG1 isotype.

[0026] In some embodiments of the disclosure, the Ab in the conjugate of formula I has a modified human IgG4 hinge region containing a S228P substitution (EU numbering), also referred to as IgG4P, which reduces IgG4 Fab arm exchange in vivo (see Labrijn, et al., Nat. Biotechnol. 2009, 27(8):767). In some embodiments, Abs with a human IgG4P backbone have improved binding to B cells and / or myeloid cells compared to human IgG4 and / or human IgG4P IL-4Rα antibodies with effector-null backbones.

[0027] In some embodiments of the disclosure, the Ab in the conjugate of formula I has a modified human IgG1 Fc region (also called IgG1A) that includes an alanine at amino acid residue 322 (K322A substitution) (EU numbering). In such embodiments, the Ab has reduced or eliminated complement activity. In some embodiments, the Ab has a modified human IgG1 Fc region (all residues numbered according to EU numbering) that includes L234A, L235A and / or P329A (also called IgG1AA or IgGIAAA, respectively) that reduces or eliminates binding to Fcγ and C1q receptors. In some embodiments, the Ab with a human IgG1A backbone shows improved binding to B cells and / or myeloid cells compared to anti-human IL-4Rα antibodies with a human IgG1AAA effector null backbone.

[0028] In some embodiments of the present disclosure, the Ab in the conjugate of formula I has a modified human IgG4 HC constant region that reduces the viscosity of the antibody compared to the same antibody having a wild-type human IgG4 HC constant region. In such embodiments, the Ab has a modified human IgG4 HC constant region that includes an amino acid substitution at any one or more of the following amino acid residues: E137G, D203N, Q274K, Q355R, E419Q (all positions are numbered according to EU numbering). In some embodiments, the Ab has a modified human IgG4 HC constant region that includes an amino acid substitution at any one or more of the following amino acid residues: E137G, D203N, Q274K, Q355R, E419Q (all positions are numbered according to EU numbering). In some embodiments, the Ab has a modified human IgG4 HC constant region that includes an amino acid substitution at any one or more of the following amino acid residues: Q274K, Q355R, E419Q (all positions are numbered according to EU numbering). In some embodiments, the Ab has a modified human IgG4 HC constant region containing amino acid substitutions at the following amino acid residues: Q274K, Q355R, E419Q (all positions numbered according to EU numbering).

[0029] In further embodiments, the Ab in the conjugate of Formula I has a modified human IgG1 or human IgG4 constant domain comprising one or more engineered cysteine ​​residues (see WO 2018 / 232088(A1)). In such embodiments, the Ab comprises a cysteine ​​at amino acid residue 124 (EU numbering) in heavy chain constant domain 1 (CH1) or at amino acid residue 378 (EU numbering) in heavy chain constant domain 2 (CH2). In other embodiments, the Ab comprises a cysteine ​​at amino acid residue 124 (EU numbering) in the CH1 domain and a cysteine ​​at amino acid residue 378 (EU numbering) in the CH2 domain.

[0030] In some embodiments, Ab in the conjugate of formula I is selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10. In some embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 have the same HCDR and LCDR amino acid sequences. Thus, as shown below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 bind to an epitope comprising amino acid residues selected from D12, M14, S15, I16, L39, F41, L42, T48, C49, I50, E52, H62, L64, M65, D66, D67, V68, V69, D72, R99, P121, P123, P124, D125, P192 (amino acid residue positions correspond to SEQ ID NO: 15). In some embodiments described below, Ab9 and Ab10 bind to an epitope on human IL-4Rα, wherein the epitope includes one or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, F41, L43, E45, H47, T48, C49, I50, H62, L64, M65, D66, D67, V69, D72, R99, P121, P123, P124, D125 (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to an epitope of human IL-4Rα, wherein the epitope includes one or more amino acid residues selected from D12, M14, S15, I16, Y37, L39, T48, C49, I50, E52, H62, M65, R99, P121, P123, P124, D125, P192, as shown below (the positions of the amino acid residues correspond to SEQ ID NO: 15). In some embodiments, as shown below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from R99, P121, P123, P124, D125, P192 (amino acid residue positions correspond to SEQ ID NO: 15), which are located in domain 2 of the N-terminal fibronectin type III domain of IL-4Rα.In some embodiments, as set forth below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to an epitope of human IL-4Rα, wherein the epitope comprises one or more amino acid residues selected from D66, D67, and D125 (amino acid residue positions correspond to SEQ ID NO: 15). In further embodiments, as set forth below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to an epitope of human IL-4Rα, wherein the epitope comprises at least one amino acid residue selected from D66 and D67 (amino acid residue positions correspond to SEQ ID NO: 15). In further embodiments as set forth below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9 and Ab10 bind to an epitope on human IL-4Rα, the epitope comprising at least one amino acid residue selected from D66 and D125 (amino acid residue positions correspond to SEQ ID NO: 15). In further embodiments as set forth below, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9 and Ab10 bind to an epitope on human IL-4Rα, the epitope comprising amino acid residue D66 (amino acid residue positions correspond to SEQ ID NO: 15). In such embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to novel structural and / or functional epitopes of human IL-4Rα, which epitopes span domain 1 and domain 2 of the n-terminal fibronectin type III domain of IL-4Rα. In certain embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to novel structural and / or functional epitopes of human IL-4Rα, which epitopes overlap with the IL-4 binding site for IL-4Rα. In such embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 inhibit binding of IL-4 to human IL-4Rα.In certain embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to novel structural and / or functional epitopes of human IL-4Rα, which overlap with the IL-13 binding site for IL-4Rα. In such embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 inhibit IL-13 binding to human IL-4Rα. In some embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 bind to novel structural and / or functional epitopes of human IL-4Rα, which overlap with the IL-4 and IL-13 binding sites for IL-4Rα. In such embodiments, Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 inhibit binding of IL-4 and IL-13 to human IL-4Rα. In some embodiments, IL-4Rα epitopes are determined by x-ray crystallography, alanine scanning mutagenesis, steric hindrance mutagenesis, and / or HDX-MS. In yet other embodiments, IL-4Rα epitopes are determined by site-directed mutagenesis.

[0031] In some embodiments, the present disclosure provides a nucleic acid encoding the HC or LC, i.e., VH or VL, of a novel antibody that binds to human IL-4Rα, or a vector comprising such a nucleic acid.

[0032] In some embodiments, the disclosure provides a nucleic acid comprising the sequence of SEQ ID NO: 11, 12, 14, 29, 30, 32, 34, 36, 38, 48, 49, 51, or 53.

[0033] In some embodiments, nucleic acids are provided that encode a heavy or light chain of an antibody that binds to human IL-4Rα. In some embodiments, nucleic acids are provided that include a sequence encoding SEQ ID NO: 9, 10, 13, 27, 28, 31, 33, 35, 37, 46, 47, 50, or 52. In some embodiments, nucleic acids are provided that include a sequence encoding an antibody heavy chain that includes SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52. For example, the nucleic acid can include a sequence of SEQ ID NO: 11, 14, 29, 32, 34, 36, 38, 48, 51, or 53. In some embodiments, nucleic acids are provided that include a sequence encoding an antibody light chain that includes SEQ ID NO: 10, 28, or 47. For example, the nucleic acid can include a sequence of SEQ ID NO: 12, 30, or 49.

[0034] In some embodiments of the present disclosure, nucleic acids are provided that encode the VH or VL of an antibody that specifically binds to human IL-4Rα. In some embodiments, nucleic acids are provided that comprise a sequence encoding SEQ ID NO: 7, 8, 25, 26, 44, or 45. In some embodiments, nucleic acids are provided that comprise a sequence encoding an antibody VH comprising SEQ ID NO: 7, 25, or 44. In some embodiments, nucleic acids are provided that comprise a sequence encoding an antibody VL comprising SEQ ID NO: 8, 26, or 45.

[0035] In some embodiments of the present disclosure, a vector is provided that comprises a nucleic acid sequence encoding an antibody heavy or light chain. For example, such a vector can comprise a nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52. In some embodiments, the vector comprises a nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47.

[0036] Also provided herein is a vector comprising a nucleic acid sequence encoding an antibody VH or VL. For example, such a vector can comprise a nucleic acid sequence encoding SEQ ID NO: 7, 25, or 44. In some embodiments, the vector comprises a nucleic acid sequence encoding SEQ ID NO: 8, 26, or 45.

[0037] Also provided herein is a vector comprising a first nucleic acid sequence encoding an antibody heavy chain and a second nucleic acid sequence encoding an antibody light chain. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52, and a second nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 13 and a second nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 27 and a second nucleic acid sequence encoding SEQ ID NO: 28. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 31 and a second nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 33 and a second nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO:35 and a second nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO:37 and a second nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO:50 and a second nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO:52 and a second nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the vector comprises a first nucleic acid sequence encoding SEQ ID NO:46 and a second nucleic acid sequence encoding SEQ ID NO:47.

[0038] Also provided herein is a composition comprising a first vector comprising a nucleic acid sequence encoding an antibody heavy chain and a second vector comprising a nucleic acid sequence encoding an antibody light chain. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 9, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 13, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 27, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 28. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 31, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:33 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:35 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:37 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:50 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:52 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:10. In some embodiments, the composition comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO:46 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:47.

[0039] Also provided herein are compositions comprising a vector comprising a nucleic acid sequence encoding an antibody heavy chain and a nucleic acid sequence encoding an antibody light chain, in some embodiments, the composition comprises a vector comprising a nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52, and a second nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47.

[0040] As used herein, the formula: [ka] "GC" in refers to a suitable glucocorticoid receptor agonist payload, including those of formula IIa, IIb, or IIc below. [ka]

[0041] As used herein, the formula: [ka] "L" in refers to a suitable linker group connecting Ab to GC. Suitable linkers known to those skilled in the art include, for example, cleavable linkers and non-cleavable linkers. More specifically, suitable linkers "L" include the following formulae IIIa-IIIf: [ka]

[0042] In one embodiment, the present disclosure provides a glucocorticoid receptor agonist payload-linker of formula IV [ka]

[0043] In one embodiment, the present disclosure provides a glucocorticoid receptor agonist payload-linker of formula IVa: [ka]

[0044] In one embodiment, the present disclosure provides a glucocorticoid receptor agonist payload-linker of formula IVb [ka]

[0045] In one embodiment, the present disclosure provides a glucocorticoid receptor agonist payload-linker of formula IVc [ka]

[0046] In one embodiment, the present disclosure provides a glucocorticoid receptor agonist payload-linker of formula IVd: [ka]

[0047] In one embodiment, the present disclosure provides a compound of formula V [ka]

[0048] In a further embodiment, the present disclosure provides a compound of formula Va [ka]

[0049] In one embodiment, the present disclosure also provides a method of treating an inflammatory disease in a subject in need of treatment thereof, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure also provides a method of treating an inflammatory disease, wherein the inflammatory disease is a type 2 inflammatory disease in a subject in need of treatment thereof, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In certain embodiments, the type 2 inflammatory disease is, for example, atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic disease, chronic obstructive pulmonary disease, or chronic spontaneous urticaria. In one embodiment, the present disclosure further provides a method of treating atopic dermatitis in a subject in need of treatment thereof, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating eosinophilic esophagitis in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating nasal polyposis in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating asthma in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating chronic sinusitis in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating an allergic disease in a subject in need thereof, comprising administering to the patient an effective amount of a conjugate of formula I or a pharma- ceutically acceptable salt thereof.In one embodiment, the present disclosure further provides a method of treating chronic obstructive pulmonary disease in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I, or a pharma- ceutically acceptable salt thereof. In one embodiment, the present disclosure further provides a method of treating chronic spontaneous urticaria in a subject in need of such treatment, comprising administering to the patient an effective amount of a conjugate of formula I, or a pharma- ceutically acceptable salt thereof.

[0050] In one embodiment, the present disclosure further provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in therapy. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment of an inflammatory disease. In certain embodiments, the inflammatory disease is a type 2 inflammatory disease. In certain embodiments, the type 2 inflammatory disease is, for example, atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic disease, chronic obstructive pulmonary disease, or chronic spontaneous urticaria. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment of atopic dermatitis. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment of eosinophilic esophagitis. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment of nasal polyposis. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment of asthma. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma-ceutically acceptable salt thereof for use in the treatment of chronic sinusitis. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma-ceutically acceptable salt thereof for use in the treatment of allergic disease. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma-ceutically acceptable salt thereof for use in the treatment of chronic obstructive pulmonary disease. In one embodiment, the present disclosure provides a conjugate of formula I or a pharma-ceutically acceptable salt thereof for use in the treatment of chronic spontaneous urticaria.

[0051] In one embodiment, the present disclosure also provides the use of the conjugate of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating an inflammatory disease. In certain embodiments, the inflammatory disease is a type 2 inflammatory disease. In certain embodiments, the type 2 inflammatory disease is, for example, atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic sinusitis, allergic disease, chronic obstructive pulmonary disease, or chronic spontaneous urticaria. In one embodiment, the present disclosure provides the use of the conjugate of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating atopic dermatitis. In one embodiment, the present disclosure provides the use of the conjugate of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating eosinophilic esophagitis. In one embodiment, the present disclosure provides the use of the conjugate of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating nasal polyposis. In one embodiment, the present disclosure provides the use of a conjugate of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of asthma. In one embodiment, the present disclosure provides the use of a conjugate of formula I or a pharma-ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of chronic sinusitis. In one embodiment, the present disclosure provides the use of a conjugate of formula I or a pharma-ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an allergic disease. In one embodiment, the present disclosure provides the use of a conjugate of formula I or a pharma-ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. In one embodiment, the present disclosure provides the use of a conjugate of formula I or a pharma-ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of chronic spontaneous urticaria.

[0052] The nucleic acid of the present disclosure can be expressed in a host cell, for example, after the nucleic acid is operably linked to an expression control sequence. Expression control sequences capable of expressing an operably linked nucleic acid are well known in the art. The expression vector can include a sequence encoding one or more signal peptides that facilitate secretion of a polypeptide from a host cell. The expression vector containing a nucleic acid of interest (e.g., a nucleic acid encoding an antibody heavy or light chain) can be transferred to a host cell by well-known methods, for example, stable or transient transfection, transformation, transduction or infection. Additionally, the expression vector can include one or more selection markers, such as, for example, tetracycline, neomycin, and dihydrofolate reductase, to aid in the detection of host cells transformed with the desired nucleic acid sequence.

[0053] In another aspect, provided herein is a cell, e.g., a host cell, comprising a nucleic acid, vector, or nucleic acid composition described herein. The host cell may be a cell stably or transiently transfected, transformed, transduced, or infected with one or more expression vectors expressing all or a portion of the antibodies described herein. In some embodiments, the host cell may be stably or transiently transfected, transformed, transduced, or infected with an expression vector expressing the HC and LC polypeptides of the antibodies of the present disclosure. In some embodiments, the host cell may be stably or transiently transfected, transformed, transduced, or infected with a first vector expressing the HC polypeptide and a second vector expressing the LC polypeptide of the antibodies described herein. Such a host cell, e.g., a mammalian host cell, may express an antibody that binds to human IL-4Rα as described herein. Mammalian host cells known to be capable of expressing antibodies include CHO cells, HEK293 cells, COS cells, and NS0 cells.

[0054] In some embodiments, a cell, e.g., a host cell, comprises a vector comprising a first nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52 and a second nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47.

[0055] In some embodiments, a cell, e.g., a host cell, comprises a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 9, 13, 27, 31, 33, 35, 37, 46, 50, or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 10, 28, or 47.

[0056] The disclosure further provides a process for producing an antibody that binds to human IL-4Rα as described herein by culturing the above-described host cells, e.g., mammalian host cells, under conditions such that the antibody is expressed, and recovering the expressed antibody from the culture medium. The medium into which the antibody is secreted may be purified by conventional techniques. Various methods of protein purification may be employed, and such methods are known in the art, e.g., see Deutscher, Methods in Enzymology 182:83-89 (1990), and Scopes, Protein Purification: Principles and Practice, 31: 1999, ... rd Edition, Springer, NY (1994).

[0057] The present disclosure provides a method of producing a conjugate, the method comprising conjugating a compound of the present disclosure with an anti-human IL-4Rα antibody.

[0058] The present disclosure provides a method of producing a conjugate comprising conjugating a compound of formula IV with an anti-human IL-4Rα antibody. The present disclosure provides a method of producing a conjugate comprising conjugating a compound of formula IVa with an anti-human IL-4Rα antibody. The present disclosure provides a method of producing a conjugate comprising conjugating a compound of formula IVb with an anti-human IL-4Rα antibody. The present disclosure provides a method of producing a conjugate comprising conjugating a compound of formula IVc with an anti-human IL-4Rα antibody. The present disclosure provides a method of producing a conjugate comprising conjugating a compound of formula IVd with an anti-human IL-4Rα antibody.

[0059] In some embodiments, the conjugate produced is a conjugate of formula I.

[0060] The present disclosure provides a method of producing a conjugate, comprising: (a) reducing an anti-human IL-4Rα antibody with a reducing agent to produce a reduced anti-human IL-4R antibody, wherein the anti-human IL-4Rα antibody comprises one or more engineered cysteine ​​residues; (b) oxidizing the reduced anti-human IL-4Rα antibody with an oxidizing agent to produce an oxidized anti-human IL-4R antibody; (c) contacting the oxidized anti-human IL-4Rα antibody with a compound of the present disclosure to produce a conjugate.

[0061] The present disclosure provides a method of producing a conjugate, comprising: (a) reducing an anti-human IL-4Rα antibody with a reducing agent, wherein the anti-human IL-4Rα antibody comprises one or more engineered cysteine ​​residues; (b) oxidizing the anti-human IL-4Rα antibody with an oxidizing agent to produce an oxidized anti-human IL-4R antibody; (c) The oxidized anti-human IL-4Rα antibody is reacted with the [ka] to produce a conjugate.

[0062] In some embodiments, the reducing agent is dithiothreitol. In some embodiments, the oxidizing agent is dehydroascorbic acid. In some embodiments, the reducing agent is dithiothreitol and the oxidizing agent is dehydroascorbic acid.

[0063] The disclosure further provides an antibody, or antigen-binding fragment thereof, produced by any of the processes described herein.

[0064] In one embodiment, the present disclosure further provides a pharmaceutical composition comprising a conjugate of formula I or a pharma- ceutically acceptable salt thereof, or an antibody, nucleic acid, or vector described herein, together with one or more pharma- ceutically acceptable carriers, diluents, or excipients. In one embodiment, the present disclosure further provides a pharmaceutical composition comprising a conjugate of formula I or a pharma- ceutically acceptable salt thereof, together with one or more pharma- ceutically acceptable carriers, diluents, or excipients. In one embodiment, the present disclosure further provides a pharmaceutical composition comprising a conjugate of formula I, together with one or more pharma- ceutically acceptable carriers, diluents, or excipients. In one embodiment, the present disclosure further provides a process for preparing a pharmaceutical composition, comprising mixing a conjugate of formula I or a pharma- ceutically acceptable salt thereof with one or more pharma- ceutically acceptable carriers, diluents, or excipients. In one embodiment, the present disclosure also encompasses novel intermediates and processes for the synthesis of the conjugate of formula I.

[0065] Detailed Description of the Invention The term "IL-4Rα" as used herein refers to any naturally occurring mature IL-4Rα resulting from processing of an IL-4Rα precursor protein in a cell, unless otherwise indicated. The term includes IL-4Rα from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys), unless otherwise indicated. The term also includes naturally occurring variants of IL-4Rα, such as splice variants or allelic variants. An exemplary amino acid sequence of human IL-4Rα is known in the art, e.g., UniProt reference sequence P24394 (SEQ ID NO: 39). An exemplary amino acid sequence of cynomolgus IL-4Rα is also known in the art, e.g., NCBI reference number XP_005591572.2 (SEQ ID NO: 40). The term "human IL-4Rα" is used herein to collectively refer to all known human IL-4Rα isoforms and polymorphic forms. The sequence numbers used herein are based on the mature protein without the signal peptide.

[0066] As used herein, unless otherwise specified, the term "IL-4R" refers to the complex of the IL-4R α subunit and the common γ chain (type I receptor) and / or the complex of the IL-4R α subunit and IL-13Rα1 (type II receptor).

[0067] The term "IL-4" as used herein refers to any naturally occurring mature IL-4 resulting from processing of IL-4 precursor protein in a cell, unless otherwise indicated. The term includes IL-4 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys), unless otherwise indicated. The term also includes naturally occurring variants of IL-4, such as splice variants or allelic variants. An example amino acid sequence of human IL-4 is known in the art, e.g., UniProt Reference SEQ ID NO: P05112 (SEQ ID NO: 17). The term "human IL-4" is used herein to collectively refer to all known human IL-4 isoforms and polymorphic forms.

[0068] The term "IL-13" as used herein refers to any naturally occurring mature IL-13 resulting from processing of IL-13 precursor protein in cells, unless otherwise indicated. The term includes IL-13 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys), unless otherwise indicated. The term also includes naturally occurring variants of IL-13, such as splice variants or allelic variants. An example amino acid sequence of human IL-13 is known in the art, e.g., UniProt Reference SEQ ID NO: P35225 (SEQ ID NO: 18). The term "human IL-13" is used herein to collectively refer to all known human IL-13 isoforms and polymorphic forms.

[0069] The term "CD23" as used herein refers to any naturally occurring mature CD23 resulting from processing of CD23 precursor protein in cells, unless otherwise stated. The term includes CD23 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys), unless otherwise stated. The term also includes naturally occurring variants of CD23, such as splice variants or allelic variants. An example amino acid sequence of human CD23 is known in the art, e.g., UniProt reference sequence number P06734 (SEQ ID NO: 41). The term "human CD23" is used herein to collectively refer to all known human CD23 isoforms and polymorphic forms.

[0070] The term "IL-4R-associated disorder" as used herein refers to a disorder associated with IL-4R-mediated signaling, such as, for example, disorders associated with type 1 IL-4R and type II IL-4R signaling. Such IL-4R-associated disorders can include, for example, immune inflammatory disorders. Such immune inflammatory disorders can include type 2 inflammatory disorders as disclosed herein. IL-4R-associated disorders can further include cancer.

[0071] The terms "modulate" or "modulates," and the like, as used herein, refer to altering or changing a measurable value, including altering or changing such a measurable value upward (i.e., upmodulating or upmodulating) or altering or changing downward (i.e., downmodulating or downmodulating).

[0072] As used herein, the term "antibody" refers to an immunoglobulin molecule that binds to an antigen. Antibody embodiments include monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, bispecific or multispecific antibodies, or conjugated antibodies. Antibodies may be of any class (e.g., IgG, IgE, IgM, IgD, IgA) and any subclass (e.g., IgG1, IgG2, IgG3, IgG4). Embodiments of the present disclosure also include antibody fragments or antigen-binding fragments, and the term "antibody fragment or antigen-binding fragment" includes at least a portion of an antibody that retains the ability to interact with an antigen, such as Fab, Fab', F(ab')2, Fv fragments, scFv, scFab, disulfide-linked Fv (sdFv), Fd fragments, and linear antibodies, which may be fused to an Fc region or an IgG heavy chain constant region.

[0073] An exemplary antibody is an immunoglobulin G (IgG) type antibody composed of four polypeptide chains: two heavy chains (HC) and two light chains (LC) cross-linked via interchain disulfide bonds. The amino terminal portion of each of the four polypeptide chains contains a variable region of about 100-125 or more amino acids that is primarily responsible for antigen recognition. The carboxy terminal portion of each of the four polypeptide chains contains a constant region that is primarily responsible for effector function. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region. The heavy chain constant region refers to the region of an antibody that includes the Fc region and CH1 domain of the antibody heavy chain. Each light chain is composed of a light chain variable region (VL) and a light chain constant region. The IgG isotype can be further divided into subclasses (e.g., IgG1, IgG2, IgG3, and IgG4). The numbering of the amino acid residues in the constant regions is based on the EU index as in Kabat. Kabat et al., Sequences of Proteins of Immunological Interest, 5 th edition, Bethesda, MD: USDept. of Health and Human Services, Public Health Service, National Institutes of Health (1991). The terms EU index numbering or EU numbering are used interchangeably herein.

[0074] The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). The CDRs are exposed on the surface of the protein and are the regions of the antibody that are important for antigen binding specificity. Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Herein, the three CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3" and the three CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3". The CDRs contain most of the residues that form specific interactions with the antigen.The assignment of amino acid residues to CDRs can be performed according to the methods described in Kabat (Kabat et al., "Sequences of Proteins of Immunological Interest", National Institutes of Health, Bethesda, Md. (1991)), Chothia (Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins", Journal of Molecular Biology, 196, 901-917 (1987), Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), North (North et al., "A New Clustering of Antibody CDR Loop Conformations", Journal of Molecular Biology, 406, 228-256 (2011)), or IMGT (the international ImMunoGeneTics This can be done by well-known schemes, including those described in the Imgt database available at www.imgt.org (see Lefranc et al., Nucleic Acids Res. 1999;27:209-212). A combination of the IMGT and North CDR definitions was used for the exemplary anti-human IL-4Rα antibodies described herein.

[0075] The term "Fc region" as used herein refers to the region of an antibody that includes the CH2 and CH3 domains of the antibody heavy chain. Optionally, the Fc region may include a portion of the hinge region or the entire hinge region of the antibody heavy chain. Biological activities, such as effector functions, are attributed to the Fc region, which vary depending on the antibody isotype. Examples of antibody effector functions include Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), C1q binding, complement-dependent cytotoxicity (CDC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptor), and activation of B cells.

[0076] The term "epitope" as used herein refers to the amino acid residues of an antigen that are bound by an antibody. An epitope can be a linear epitope, a conformational epitope, or a hybrid epitope. The term "epitope" can be used in reference to a structural epitope. A structural epitope can be used according to some embodiments to describe the area of ​​an antigen that is covered by an antibody (e.g., the footprint of an antibody when bound to the antigen). In some embodiments, a structural epitope can describe amino acid residues of an antigen that are within a certain proximity (e.g., within a certain number of angstroms) of amino acid residues of an antibody. The term "epitope" can also be used in reference to a functional epitope. A functional epitope can be used according to some embodiments to describe amino acid residues of an antigen that interact with amino acid residues of an antibody in a manner that contributes to the binding energy between the antigen and the antibody. Epitopes can be determined according to different experimental techniques, also called "epitope mapping techniques". It is understood that the determination of an epitope may vary based on the different epitope mapping techniques used, and may also vary with different experimental conditions used, for example, due to conformational changes or cleavage of the antigen induced by the particular experimental conditions. Epitope mapping techniques are known in the art (e.g., Rockberg and Nilvebrant, Epitope Mapping Protocols: Methods in Molecular Biology, Humana Press, 3rd ed. 2018; Holst et al., Molecular Pharmacology 1998, 53(1):166-175), including, but not limited to, X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, site-directed mutagenesis, species-exchange mutagenesis, alanine scanning mutagenesis, steric hindrance mutagenesis, hydrogen-deuterium exchange (HDX), and cross-blocking assays.

[0077] The term "bind," as used herein, unless otherwise specified, is intended to mean the ability of a protein or molecule to form a chemical bond or attractive interaction with another protein or molecule, resulting in the proximity of the two proteins or molecules, as determined by common methods known in the art.

[0078] The term "nucleic acid" as used herein refers to a polymer of nucleotides, including single- and / or double-stranded nucleotide-containing molecules, such as DNA, cDNA, and RNA molecules, that incorporate naturally occurring nucleotides, modified nucleotides, and / or nucleotide analogs. A polynucleotide of the disclosure can also include substrates incorporated therein, for example, by a DNA or RNA polymerase or a synthetic reaction.

[0079] Embodiments of the present disclosure include conjugates in which a polypeptide (e.g., an anti-human interleukin-4 receptor alpha antibody) is conjugated to one or more drug moieties, e.g., two drug moieties, three drug moieties, four drug moieties, five drug moieties, or more drug moieties. The drug moieties may be conjugated to the polypeptide at one or more sites in the polypeptide, as described herein. In certain embodiments, the conjugates have an average drug-to-antibody ratio (DAR) (molar ratio) ranging from 2 to 5, or 3 to 5, or 3 to 4. In certain embodiments, the conjugates have an average DAR of 3 to 4. In certain embodiments, the conjugates have an average DAR of about 3. In certain embodiments, the conjugates have an average DAR of about 4.

[0080] As used herein, conjugates of formula I are understood to encompass conjugates of formulae Ia, Ib, Ic, Id, Ie, and If, and all references herein to conjugates of formula I should be read as including conjugates of formulae Ia, Ib, Ic, Id, Ie, and If. It will be further understood by those skilled in the art that conjugates of formula I, including conjugates of formulae Ia, Ib, Ic, Id, Ie, and If, can also be referred to as anti-human IL-4Rα antibody glucocorticoid conjugates ("anti-human IL-4Rα Ab GC conjugates").

[0081] The anti-human IL-4Rα antibody GC conjugate of the present disclosure may be formulated as a pharmaceutical composition, which may be administered by any route that renders the conjugate bioavailable, including, for example, intravenous or subcutaneous administration. Such pharmaceutical compositions may be prepared using techniques and methods known in the art (see, for example, Remington: The Science and Practice of Pharmacy, A. Adejare, Editor, 23rd Edition). nd Edition, published in 2020, see Elsevier Science).

[0082] As used herein, the terms "treating", "treatment" or "to treat" include inhibiting, slowing, halting, controlling, retarding or reversing the progression or severity of an existing condition or disorder, or ameliorating an existing condition or disorder, but do not necessarily indicate the complete elimination of an existing condition or disorder. Treatment includes the administration of a protein or nucleic acid or vector or composition for the treatment of a condition or disorder to a patient, particularly a human.

[0083] The term "inhibit" or "inhibiting" as used herein refers to, for example, reducing, decreasing, slowing, diminishing, halting, disrupting, eliminating, antagonizing, or blocking a biological response or activity, but does not necessarily indicate a complete elimination of the biological response.

[0084] As used herein, the term "subject" refers to a mammal, including, but not limited to, humans, chimpanzees, apes, monkeys, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, mice, guinea pigs, etc. Preferably, the subject is a human.

[0085] As used herein, the term "effective amount" refers to an amount or dosage of a conjugate of the present disclosure or a pharma- ceutically acceptable salt thereof that, when administered to a subject in a single or multiple doses, provides a desired effect to a subject during diagnosis or treatment. The term "effective amount" as used herein further refers to an amount of a conjugate of the present disclosure or a pharma- ceutically acceptable salt thereof that induces a desired biological or medical response in a subject, e.g., induces a reduction or inhibition of a protein's activity, or improves symptoms, alleviates a condition, slows or delays the progression of a disease, or prevents a disease, etc. In a non-limiting embodiment, the term "effective amount" refers to the necessary amount (dosage and duration and means of administration) of a conjugate or a pharma- ceutically acceptable salt thereof that, when administered to a subject, is effective to at least partially alleviate, inhibit, prevent, and / or ameliorate a condition, or a disorder or disease, to achieve a desired therapeutic result. An effective amount is also an amount in which the beneficial effects outweigh the toxic or harmful effects of a conjugate of the present disclosure or a pharma- ceutically acceptable salt thereof.

[0086] Effective amounts can be determined by those skilled in the art by using known techniques and observing results obtained under similar circumstances. In determining the effective amount for a patient, the attending physician will take into account, but is not limited to, the patient's species; its size, age, and general health; the specific disease or disorder involved; the extent or involvement or severity of the disease or disorder; the response of the individual patient, the specific conjugate administered, the mode of administration; the bioavailability characteristics of the administered preparation; the selected dosing regimen; the use of concomitant drugs; and other relevant circumstances.

[0087] Included within the scope of the present invention are pharma- ceutically acceptable salts of the conjugates of formula I. Pharmaceutically acceptable salts of the conjugates of the present invention, such as the conjugates of formula I, can be formed under standard conditions known in the art. See, for example, Berge, SM, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66:1-19, (1977).

[0088] [Table 1]

[0089] The conjugates or salts thereof of the present disclosure may be readily prepared by a variety of procedures known to those skilled in the art, some of which are described in the following preparations and examples. Those skilled in the art will recognize that the specific synthetic steps for each of the described routes can be combined in different ways or combined with steps from different schemes to prepare the conjugates or salts thereof of the present disclosure. The products of each step can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization. All substituents are as previously defined unless otherwise indicated. The reagents and starting materials are readily available to those skilled in the art. The following preparations, examples, and assays further illustrate the present invention, but should not be construed as limiting the scope of the present invention in any way. [Brief description of the drawings]

[0090] [Figure 1] 1 shows an X-ray crystal structure overlay of the Fab portion of Ab9 bound to IL-4Rα ECD with the crystal structure of the dupilumab Fab portion with Crystal Kappa design complexed with human IL-4Rα (pdb accession code 6WGL). [Diagram 2]Shown is the functional epitope amino acid residue position (human IL-4Rα residues Asp66 and Asp125) in the crystal structure of Ab10 Fab portion with Crystal Kappa design complexed with human IL-4Rα ECD. [Diagram 3] 1 shows an X-ray crystal structure overlay of the Fab portion of Ab1 bound to IL-4Rα ECD with the crystal structure of the dupilumab Fab portion with Crystal Kappa design complexed with human IL-4Rα (pdb accession code 6WGL). [Figure 4] Shown is human IL-4Rα amino acid residue positions Asp66, Asp67, and Asp125 in the crystal structure of Ab1 Fab portion with Crystal Kappa design complexed with human IL-4Rα ECD (all identified in structural epitopes. Additionally, Asp66 has been identified in a functional epitope). [Diagram 5] FIG. 1 shows inhibition of anti-CD40-induced B cell proliferation by the Ab1GC conjugate of Example 1b. [Figure 6A] 6A shows inhibition of IL-4-induced CD23 expression (6A) and GC-induced CD163 expression (6B) in bone marrow cells by the Ab1GC conjugate of Example 1b. [Figure 6B] 6A shows inhibition of IL-4-induced CD23 expression (6A) and GC-induced CD163 expression (6B) in bone marrow cells by the Ab1GC conjugate of Example 1b. [Figure 7A] 7A-7C show that the Ab1GC conjugate of Example 1b significantly inhibited IL-4Rα-mediated MDC (7A), GM-CSF (7B), and glucocorticoid receptor-mediated IL-5 (7C) cytokine secretion. [Figure 7B] 7A-7C show that the Ab1GC conjugate of Example 1b significantly inhibited IL-4Rα-mediated MDC (7A), GM-CSF (7B), and glucocorticoid receptor-mediated IL-5 (7C) cytokine secretion. [Figure 7C]7A-7C show that the Ab1GC conjugate of Example 1b significantly inhibited IL-4Rα-mediated MDC (7A), GM-CSF (7B), and glucocorticoid receptor-mediated IL-5 (7C) cytokine secretion. [Figure 8] 1 shows that the Ab1GC conjugate of Example 1b does not significantly induce ADCC activity. [Figure 9] FIG. 1 shows that the Ab1GC conjugate of Example 1b does not induce CDC activity in Daudi cells. [Figure 10A] 1 shows differential scanning calorimetry (DSC) thermograms for an exemplary AblGC conjugate of Example 1b under the following conditions: PBS, pH 7.2 (10A); acetate, pH 5 (10B); and histidine, pH 6 (10C). [Figure 10B] 1 shows differential scanning calorimetry (DSC) thermograms for an exemplary AblGC conjugate of Example 1b under the following conditions: PBS, pH 7.2 (10A); acetate, pH 5 (10B); and histidine, pH 6 (10C). [Figure 10C] 1 shows differential scanning calorimetry (DSC) thermograms for an exemplary AblGC conjugate of Example 1b under the following conditions: PBS, pH 7.2 (10A); acetate, pH 5 (10B); and histidine, pH 6 (10C).

[0091] Preparation 1 6-Bromo-2-fluoro-3-methoxybenzaldehyde [ka] Two reactions were carried out in parallel. To a solution of 4-bromo-2-fluoro-1-methoxybenzene (250 g, 1.2 mol) in THF (1500 mL) was added LDA (2M, 730 mL) slowly over 30 min at -78 °C. After another 30 min, DMF (140 mL, 1.8 mol) was added slowly over 30 min at -78 °C. After 1 h, the two reactions were combined and the mixture was diluted with aqueous citric acid (2000 mL) and extracted with EtOAc (1500 mL x 2). The combined organic layers were washed with saturated aqueous NaCl (1000 mL) and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (1000 mL) at room temperature for 12 h to give the title compound (382 g, 67% yield). ES / MS m / z 233.9 (M+H).

[0092] Preparation 2 2-Fluoro-3-methoxy-6-methylbenzaldehyde [ka] Three reactions were carried out in parallel. 6-Bromo-2-fluoro-3-methoxybenzaldehyde (120 g, 5.3 mol), methylboronic acid (47 g, 7.9 mol), Pd(dppf)Cl2 (12 g, 0.02 mol), and Cs2CO3 (340 g, 1.1 mol) were added to a mixture of 1,4-dioxane (600 mL) and water (120 mL). The mixture was stirred at 120 °C. After 12 h, the three reactions were combined and the mixture was diluted with saturated aqueous NH4Cl (1000 mL) and extracted with MTBE (1500 mL x 2). The combined organic layers were washed with satd aq NaCl (1000 mL) and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography eluting with 40:1 Pet ether:EtOAc to give the title compound (180 g, 59%). ES / MS m / z 169.3 (M+H).

[0093] Preparation 3 2-Fluoro-3-hydroxy-6-methylbenzaldehyde [ka] 2-Fluoro-3-methoxy-6-methylbenzaldehyde (175 g, 1.0 mol) was added in DCM (1050 mL). BBr3 (200 mL, 2.1 mol) was added slowly to the solution at 0 °C. The reaction was stirred at room temperature. After 1 h, the mixture was diluted with saturated aqueous NaHCO3 (1000 mL) until pH = 7-8 and extracted with MTBE (1500 mL x 2). The combined organic layers were washed with saturated aqueous NaCl (1000 mL) and concentrated under reduced pressure to give the title compound (110 g, 68%). ES / MS m / z 154.9 (M+H).

[0094] Preparation 4 tert-Butyl N-[3-[(2-fluoro-3-formyl-4-methyl-phenoxy)methyl]phenyl]carbamate [ka] 2-Fluoro-3-hydroxy-6-methylbenzaldehyde (130 g, 0.84 mol), tert-butyl (3-(bromomethyl)phenyl)carbamate (200 g, 0.70 mol), and potassium carbonate (350 g, 2.5 mol) were added to acetonitrile (780 mL) at room temperature and then heated to 50° C. After 5 h, the reaction was diluted with water (600 mL) and extracted with EtOAc (800 mL×2). The combined organic layers were washed with saturated aqueous NaCl (800 mL) and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography eluting with 50:1 Pet ether:EtOAc to give the crude product. The crude product was triturated with MTBE (500 mL) at room temperature for 30 min to give the title compound (103 g, 32%). ES / MS m / z 382.1 (M+Na).

[0095] Preparation 5 (6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-(3-((3-aminobenzyl)oxy)-2-fluoro-6-methylphenyl)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one [ka] Perchloric acid (70% in water, 4.8 mL) was added to a suspension of (8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (4.4 g, 12 mmol, also referred to as "16alpha-hydroxyprednisolone") and tert-butyl N-[3-[(2-fluoro-3-formyl-4-methyl-phenoxy)methyl]phenyl]carbamate (4.0 g, 11 mmol, Preparation 4) in acetonitrile (110 mL) at -10°C and allowed to warm to room temperature. After 1 h, DMF (10 mL) was added to the suspension at room temperature. After 18 h, the reaction was quenched with saturated aqueous NaHCO3 and extracted with 9:1 DCM:isopropanol. The organic layers were combined, dried over MgSO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase chromatography eluting with 1:1 aqueous NH4HCO3 (10 mM+5% MeOH):ACN to give the title compound, peak 1 (1.72 g, 25%). ES / MS m / z 618.6 (M+H). 1H NMR(400.13MHz,d6-DMSO)δ0.93~0.87(m,6H),1.40(s,3H),1.71~1.60(m,1H),1.89~1.76(m,4H),2.1 8~2.12(m,2H),2.29(s,4H),4.23~4.17(m,1H),4.32~4.30(m,1H),4.50~4.43(m,1H),4.81(d,J=3.2Hz) ,1H),4.98~4.95(m,3H),5.16~5.10(m,3H),5.61(s,1H),5.95(s,1H),6.18~6.15(m,1H),6.53~6.48(m ,2H),6.58(s,1H),6.90~6.86(m,1H),6.99(t,J=7.7Hz,1H),7.12(t,J=8.5Hz,1H),7.33~7.30(m,1H).

[0096] Preparation 6 (6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-10-(3-((3-aminobenzyl)oxy)-2-fluoro-6-methylphenyl)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (also referred to herein as GC1) [ka] From preparation 5, the residue was purified by reverse phase chromatography eluting with 1:1 aqueous NH4HCO3 (10 mM + 5% MeOH):ACN to give the title compound, peak 2 (1.24 g, 18%). ES / MS m / z 618.6 (M+H). 1 H NMR (400.13MHz, d6-DMSO) 1H NMR(400.13MHz,DMSO):0.88(s,3H),1.24~1.12(m,2H),1.40(s,3H),1.69~1.56(m,1H),1.91~1.76(m,4H),2.08~2.01(m ,2H),2.22(s,3H),2.39~2.29(m,1H),3.18(d,J=5.2Hz,1H),4.12~4.00(m,1H),4.37~4.30(m,2H),4.79(d,J=3.1Hz,1H) ,5.00~4.93(m,2H),5.10~5.06(m,3H),5.31(d,J=6.7Hz,1H),5.95(s,1H),6.18(dd,J=1.8,10.1Hz,1H),6.34(s,1H),6. 53~6.48(m,2H),6.58(s,1H),6.87(d,J=8.5Hz,1H),6.99(t,J=7.7Hz,1H),7.09(t,J=8.5Hz,1H),7.33(d,J=10.1Hz,1H).

[0097] Preparation 7 (3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl)-L-alanyl-L-alanine [ka] To a solution of N-succinimidyl 3-maleimidopropionate (5.0 g, 19 mmol) and L-alanyl-L-alanine (3.4 g, 21 mmol) in DMF (25 mL) was added DIPEA (3.1 mL, 18 mmol) and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give a residue, which was purified by silica gel chromatography eluting with 2% acetic acid in EtOAc to give the title compound (4.0 g, 69%). ES / MS m / z 312.3 (M+H).

[0098] Preparation 8 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((3-((2-fluoro-3-((6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-4-oxo-2,4,6a,6b,7,8, 8a,8b,11a,12,12a,12b-Dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-10-yl)-4-methylphenoxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)propanamide (also referred to herein as "GC-L") [ka] (6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-10-(3-((3-aminobenzyl)oxy)-2-fluoro-6-methylphenyl)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2 A solution of -d][1,3]dioxol-4-one (GC1, 24 g, 39 mmol, see Preparation 6) and 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl)-L-alanyl-L-alanine (15 g, 47 mmol, see Preparation 7) in DMF (250 mL) was cooled to 0-5 °C and 2,6-lutidine (11 mL, 97 mmol) was added followed by HATU (17 g, 43 mmol). The mixture was stirred at 0-5 °C for 5 min, then the cooling bath was removed and the mixture was stirred for 2 h. The mixture was diluted with EtOAc. The organic solution was washed three times with water and once with saturated aqueous NaCl, dried over Na2SO4 (MeOH was added to aid solubility), filtered and evaporated to give the crude product. The crude product was purified by silica gel chromatography using a gradient of 1-10% MeOH in DCM to give the title compound (24 g, 68%). ES / MS m / z 911.4 (M+H). 1H NMR(400.13MHz,DMSO):d 9.88(s,1H),8.20(d,J=7.1Hz,1H),8.11(d,J=7.2Hz,1H),7.68(s,1H),7.60-7.58(m,1H),7.34-7.29(m,2H),7.14-7.09(m, 2H),7.00(s,2H),6.89(d,J=8.4Hz,1H),6.34(s,1H),6.18(dd,J=1.8,10.0Hz,1H),5.95(s,1H),5.76(s,1H),5.31(d,J=6.8 Hz,1H),5.13-5.04(m,3H),4.78(d,J=3.1Hz,1H),4.41-4.30(m,4H),4.10-4.00(m,1H),3.61(t,J=7.3Hz,2H),2.42-2.31(m ,3H),2.22(s,3H),2.11-2.01(m,2H),1.91-1.78(m,5H),1.40(s,3H),1.31(d,J=7.2Hz,3H),1.19-1.11(m,5H),0.88(s,3H).

[0099] Preparation 9 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((3-((2-fluoro-3-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-4-oxo-2,4 ,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-10-yl)-4-methylphenoxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)propanamide [ka] In a manner similar to the procedure described in Preparation 8, the compound of Preparation 9 was prepared from (6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-(3-((3-aminobenzyl)oxy)-2-fluoro-6-methylphenyl)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (see Preparation 5) and 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl)-L-alanyl-L-alanine (see Preparation 7). ES / MS m / z 911.4(M+H). 1H NMR(500.11MHz,DMSO):d 9.88(s,1H),8.23-8.20(m,1H),8.11(d,J=7.2Hz,1H),7.69(s,1H),7.59(d,J=8.0Hz,1H),7.33-7.28(m,2H),7.15-7.08(m, 2H),7.00(s,2H),6.91-6.89(m,1H),6.17(dd,J=1.7,10.1Hz,1H),5.94(s,1H),5.61(s,1H),5.16-5.12(m,3H),4.98-4.96( m,1H),4.81(d,J=3.1Hz,1H),4.49-4.36(m,6H),3.61(t,J=7.3Hz,2H),2.41(t,J=7.3Hz,2H),2.30-2.29(m,4H),2.17-2.15 (m,2H),1.88-1.77(m,4H),1.69-1.61(m,1H),1.40(s,3H),1.31(d,J=7.2Hz,3H),1.18(d,J=7.2Hz,3H),0.93-0.87(m,6H). EXAMPLES

[0100] Example 1. Preparation of anti-human IL-4Rα antibody GC conjugate Example 1a. Generation and Engineering of Anti-Human IL-4Rα Antibodies Antibody generation: To develop antibodies specific for human IL-4Rα, transgenic mice carrying human immunoglobulin variable regions were immunized with Fc-tagged extracellular domain (ECD) of human IL-4Rα and alternately boosted with human and cynomolgus Fc-tagged IL-4Rα ECD proteins. Screening was performed using histidine-tagged human and cynomolgus IL-4Rα ECD to identify cross-reactivity, and in the absence or presence of excess soluble IL-4 to identify IL-4 blocking antibodies. Cross-reactive antibodies were cloned as Fabs, expressed, purified by standard procedures, and tested for blocking activity against IL-4 and IL-13 in a reporter cell line, human embryonic kidney (HEK)-Blue IL-4 / IL-13 (InvivoGen). Antibodies were selected and their CDRs, variable domain framework regions, and IgG isotype were engineered to improve properties such as affinity, stability, solubility, viscosity, hydrophobicity, and reduced aggregation.

[0101] The amino acid sequence of human IL-4RαECD is defined by SEQ ID NO:15, the amino acid sequence of cynomolgus monkey IL-4RαECD is defined by SEQ ID NO:16, the amino acid sequence of human IL-4 is defined by SEQ ID NO:17, and the amino acid sequence of human IL-13 is defined by SEQ ID NO:18.

[0102] The antibodies of the present invention can be synthesized and purified by well-known methods. Suitable host cells, such as Chinese Hamster Ovary cells (CHO), can be transiently or stably transfected with an expression system for secreting antibodies using a defined HC:LC vector ratio when two vectors are used, or using a single vector system encoding both the heavy and light chains. The clarified medium into which the antibodies are secreted can be purified using commonly used techniques.

[0103] Antibody engineering for affinity and biophysical properties: The IL-4Rα antibody Ab10 was engineered as a Fab in a mammalian cell expression vector using a high-throughput, site-directed, saturation mutagenesis protocol to find mutations that improve affinity and / or biophysical properties (stability, solubility, viscosity, hydrophobicity, aggregation, serum protein binding, thermal or chemical stability, etc.).

[0104] Briefly, CDR mutagenesis and atypical germline residues in the framework regions of Ab10 were evaluated. CDR analysis identified key CDR substitutions: LCDR3 H91W, N92S, which increased the affinity of the resulting antibody by 10. -9 M range to 10 -11M range. Further analysis and experimentation identified key residue modifications in VH: A23V, N92S, I31H; VL: G28D that improved thermostability in heat challenge ELISA while maintaining affinity. In addition, amino acid residue substitutions in VH: A23V, I58V; VL: G28D were found to reduce self-association and hydrophobicity while maintaining affinity. Amino acid residue substitution: VH: I31H was found to reduce serum protein binding. Certain antibodies were further engineered to eliminate deamidation by replacing asparagine (N72) in HC framework 3 with aspartic acid (N72D). In summary, seven key amino acid residues were identified and engineered into Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7 and Ab8 as follows in VH: A23V, I31H, I58V, N72D and VL: G28D, H91W, N92S, which significantly improved the affinity and biophysical properties (shown below) of the anti-human IL-4Rα antibodies, such as thermal stability, reduced self-association, hydrophobicity, and / or serum protein binding, without adversely affecting other functional or biophysical properties of the antibodies. Ab9 was engineered with amino acid residue substitutions in VH: I31H, I58V, N72D and VL: H91W, N92S as follows. Table 2 shows the CDR amino acid sequences of the exemplary antibodies. Exemplary antibodies were generated using different IgG scaffolds, including those provided in Table 3.

[0105] Antibody hinge and Fc scaffold selection: Anti-human IL-4Rα antibodies Ab1, Ab2, Ab3, Ab4, Ab5, Ab9 and Ab10 were engineered to contain the S228P mutation, which stabilizes the hinge and prevents arm exchange. The constructs were completed using wild-type IgG4 domains with human kappa constant domains. Antibodies were synthesized, expressed and purified essentially as described above.

[0106] Human IgG1A and / or human IgG4P scaffolds were chosen for the exemplified antibodies because they offered unexpected advantages in binding to B cells and myeloid cells. As shown below, the exemplified antibodies were found to have greater binding potency to B cells when compared to effector-null antibodies, thus indicating that the Fc portions of the exemplified antibodies that were not engineered to be effector-null positively impacted B cell binding of the anti-IL-4Rα antibodies.

[0107] Antibody constant region engineering to improve viscosity: To improve viscosity and reduce potential electrostatic interactions between the Fab and constant domains of the antibody, the anti-human IL-4Rα antibody heavy chain constant region was further engineered by charge balancing. Five key amino acid residues in the CH1, CH2, and CH3 domains in IgG4 were identified as affecting the viscosity of anti-human IL-4Rα antibodies: 1) E137 (CH1 domain), 2) D203 (CH1 domain), 3) Q274 (CH2 domain), 4) Q355 (CH3 domain), and 5) E419 (CH3 domain). To significantly improve the viscosity of the antibody, antibodies with various combinations of these amino acid substitutions were generated, including a combination of Q274K (CH2 domain), Q355R (CH3 domain), and E419Q (CH3 domain) for Ab1. The analogous positions in the hIgG1 constant region for the five amino acids were found to be different and affect the overall pI of each domain.

[0108] [Table 2]

[0109] [Table 3]

[0110] Example 1b. Generation of anti-human IL-4Rα Ab1GC conjugates (n=4) [ka] wherein n is 4; Ab is Ab1.

[0111] Exemplary anti-human IL-4Rα Ab1 (see Tables 2 and 3) was first reduced in the presence of a 40-fold molar excess of dithiothreitol (DTT) for 2 hours at 37° C. or >16 hours at 21° C. This initial reduction step was used to remove various capping groups including cysteine ​​and glutathione attached to cysteines engineered at positions 124 and 378 of the heavy chain during expression. After the reduction step, the samples were purified through a desalting resin to remove the cysteine ​​caps as well as the reducing agent. A subsequent 2-hour oxidation step was performed at room temperature (approximately 21° C.) in the presence of a 10-fold molar excess of dehydroascorbic acid (DHAA) to reform native interchain disulfide and hinge disulfide pairs between the light and heavy chains. After the 2 hour oxidation step, 4 to 8 molar equivalents of glucocorticoid receptor agonist payload-linker ("GC-L"), 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((3-((2-fluoro-3-((6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a, 8a-Dimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-10-yl)-4-methylphenoxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)propanamide was added using a 10 mM stock solution dissolved in DMSO. The sample was then incubated at room temperature for 30-60 min to allow efficient conjugation of LPs to the engineered cysteines. The sample was then buffer exchanged into the appropriate formulation buffer using a subsequent polishing step such as size exclusion chromatography (SEC) or tangential flow filtration (TFF) to remove DMSO and any excess linker-payload.

[0112] Drug-to-Antibody Ratio (DAR) Assessment: To assess the average number of linker-payloads present on the final conjugates, two analytical methods were used including 1) reversed-phase (RP) HPLC and 2) time-of-flight (TOF) mass spectrometry. Both methods required an initial sample reduction step involving the addition of dithiothreitol (DTT) to a final concentration of approximately 10 mM, followed by incubation at 42° C. for 5 min.

[0113] Reverse Phase HPLC Method: 1 mg / mL anti-human IL-4Rα antibody GC conjugate samples were reduced by incubating the samples in the presence of 10 mM DTT at 42°C for 5 minutes. 10-30 micrograms of reduced anti-human IL-4Rα antibody GC conjugate sample were injected onto a Phenyl 5PW, 4.6 mm x 7.5 cm, 10 μM column (Tosh Part#0008043). Buffer A consisted of 0.1% trifluoroacetic acid (TFA) in water, while buffer B consisted of 0.1% trifluoroacetic acid (TFA) in acetonitrile (ACN). The column was equilibrated in 20% B buffer prior to sample injection, followed by a gradient of 28% B to 40% B over approximately 8.5 column volumes. The average DAR was determined by calculating the contribution from each individual DAR species from the fraction percentage multiplied by the DAR number per contributing species. Since this value is based on a reduced sample and represents only half of the molecule, the number was then multiplied by 2 to account for the intact antibody GC conjugate. The DAR calculation for the anti-human IL-4Rα Ab1 GC conjugate of Example 1b is provided in Table 4.

[0114] [Table 4]

[0115] Time-of-Flight Mass Spectrometry: 8 μg of reduced sample was injected onto a Poroshell 300sb-C3 2.1×2.5 mm, 5 μM column (Agilent Part#821075-924). Buffer A consisted of 0.1% trifluoroacetic acid (TFA) in water, while buffer B consisted of 0.1% trifluoroacetic acid (TFA) in acetonitrile (ACN). The column was equilibrated in 0% B buffer prior to sample injection, followed by a gradient from 10% B to 80% B over approximately 28 column volumes. The average DAR was determined by calculating the contribution from each individual DAR species from the fraction percentage multiplied by the DAR number for each contributing species. Since this value is based on reduced sample and represents only half of the molecule, the number was multiplied by 2 to account for intact antibody. The DAR calculation for the anti-human IL-4Rα Ab1GC conjugate of Example 1b is provided in Table 5.

[0116] [Table 5]

[0117] Example 1c. Generation of anti-human IL-4Rα Ab1GC conjugate (n=3) [ka] wherein n is 3; Ab is Ab1.

[0118] The conjugate of Example 1c was prepared in a similar manner to the procedure described in Example 1b, using a lower molar ratio of GC-L, 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((3-((2-fluoro-3-((6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl -4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-10-yl)-4-methylphenoxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)propanamide was prepared using Ab1 during the conjugation step. For example, the use of a 3.2:1 molar ratio of the corresponding GC-L:Ab1 results in a final DAR of about 3.

[0119] Example 1d. Thiosuccinimide Hydrolysis: The thiosuccinimide ring of a compound of formula Ie can be hydrolyzed under conditions well known in the art (see, e.g., WO 2017 / 210471, paragraph 001226), as shown in Scheme 1 below, to give the ring-opened product of formula If.

[0120] Scheme 1 [ka] Additionally, the thiosuccinimide ring of compounds of formula Ie may undergo at least partial hydrolysis in vivo under standard or well-known formulation conditions to provide ring-opened products of formula If.

[0121] Example 2. Structural and functional epitope determination of anti-human IL-4Rα antibody Example 2a. Structural epitope of Ab9Fab by X-ray crystallography. The physical epitope of the Fab of anti-IL-4Rα Ab9 on human IL-4Rα was determined by identifying the interaction interface between human IL-4Rα and the exemplified antibody. Briefly, to determine the structural epitope, human IL-4Rα ECD was co-crystallized with the Fab portion of Ab9. The structure of Ab9Fab complexed with IL-4Rα was determined by making a hexahistidine-tagged IgG1 variant of the heavy chain truncated after the CH1 domain and a "Crystal Kappa" version of the light chain of Ab9Fab (see Lieu et al., "Rapid and Robust Antibody Fab Fragment Crystallization Utilizing Edge-to-edge Beta-sheet Packing," PLoS One, 15(9) (2020), incorporated herein by reference in its entirety). The Ab9 variants were co-expressed with a hexahistidine-tagged version of human IL-4Rα ECD containing the C182L mutation, and the complexes were then purified by immobilized metal affinity chromatography and screened using standard commercial screens for crystallization. Crystals were obtained and X-ray diffraction data were collected at the Advanced Photon Source. The diffraction data were reduced and analyzed by molecular replacement and refined to obtain a 2.8 angstrom structure of the illustrated complex of Ab9Fab and IL-4Rα ECD. From the resulting crystal structure, any IL-4Rα amino acid residue within 4.5 angstroms of an atom of the co-crystallized Ab9Fab was counted as part of the epitope (using PyMOL visualization software [Schrodinger®]).

[0122] PyMOL analysis demonstrated that IL-4Rα amino acid residues within 4.5 angstroms of Ab9Fab in the crystal structure complex (with respect to SEQ ID NO:15) contain the structural epitope of the exemplified antibody. Specifically, the analysis determined that the structural epitope includes the following amino acid residues: Asp at position 12, Met at position 14, Ser at position 15, Ile at position 16, Tyr at position 37, Leu at position 39, Phe at position 41, Leu at position 43, Glu at position 45, His at position 47, Thr at position 48, Cys at position 49, Ile at position 50, His at position 62, Leu at position 64, Met at position 65, Asp at position 66, Asp at position 67, Val at position 69, Asp at position 72, Arg at position 99, Pro at position 121, Pro at position 123, Pro at position 124, and Asp at position 125. The analysis further determined that the structural epitope spans domains 1 and 2 of the N-terminal fibronectin type III domain of IL-4Rα. Further analysis determined that the following amino acid residues of the structural epitope are located in domain 2 of the N-terminal fibronectin type III domain of IL-4Rα: R99, P121, P123, P124, D125.

[0123] Additionally, an overlay of the illustrated crystal structures of Ab9Fab and dupilumab Fab with a crystal kappa design complexed with human IL-4Rα (pdb accession code 6WGL) showed that Ab9Fab binds to a novel epitope on IL-4Rα when compared to dupilumab (Figure 1).

[0124] Furthermore, alignment (using PyMOL visualization software) of the exemplary IL-4Rα Ab9Fab:IL-4Rα complex crystal structure with published complexes of IL-4 and IL-13 and their respective receptors (pdb accession codes 3BPN and 3BPO) on the IL-4Rα component in each structure showed that the exemplary Ab9Fab antibody epitope overlaps with both the IL-4 and IL-13 binding sites on IL-4Rα, thus indicating that when the Fab variant portion of the exemplary antibody binds to IL-4Rα, binding of the exemplary antibody to IL-4Rα physically blocks the binding of IL-4 and IL-13 cytokines to IL-4Rα.

[0125] Example 2b. Functional epitope of Ab10. The functional epitope of the exemplified anti-human IL-4Rα Ab10 was determined by ELISA. Briefly, 30 surface amino acid residue substitutions were individually introduced into the hexahistidine-tagged human IL-4Rα extracellular domain (ECD) as follows: K2D, E6R, K22D, P26R, T31R, F41A, L42G, L43G, E45R, G56R, D66R, A71R, Q82G, K87D, E94R, H107A, D108R, P124R, D125R, D143R, R148D, L155R, R160D, S164R, S168R, Q181R, P192R, K195D, or H197G. Each mutein with a single amino acid residue substitution as described above was transiently expressed in CHO cells and purified using standard immobilized metal affinity chromatography techniques. ELISA plates were coated with 1 μg / mL goat anti-human kappa antibody (Southern Biotech, Cat. No. 2060-01) in PBS overnight at 4° C., then washed three times with PBST and blocked with PBS-casein for 30 minutes at room temperature. The plates were then washed three times with PBST, and the exemplified anti-human IL-4Rα antibody Ab6 was added to the wells at a final concentration of 1 μg / mL in PBS-casein and incubated for 1 hour. The plates were washed three times with PBST, and the IL-4Rα muteins were serially diluted 3-fold from 1 μg / mL in PBS-casein, added to the plates at 50 μL / well, and incubated at room temperature for 1 hour. Plates were washed 3 times with PBST and a 5000-fold dilution of anti-histidine tag antibody HRP conjugate (R&D Systems, Cat. No. MAB050H) in PBS-casein was added and incubated for 1 hour at room temperature. Plates were washed 3 times and TMB substrate (Pierce, Cat. No. 34021) was added according to the manufacturer's instructions, the reaction was quenched with H2SO4 and absorbance was read at 450 nm in an ELISA plate reader. The functional epitope of the antibody was determined as the mutated amino acid residue corresponding to wells that showed no binding signal or a significantly reduced binding signal compared to the control antibody.

[0126] The results in Table 6A show that the functional epitope of the exemplified anti-human IL-4Rα Ab10 includes amino acid residues D66 and D125. Among the amino acid residues identified in the structural epitope, amino acid residue substitutions of D66R and D125R on IL-4Rα, respectively, showed a significant negative effect on the binding of Ab10 to mutant IL-4Rα. Specifically, substitution of amino acid residue D66 of IL-4Rα with arginine reduced the binding of Ab10 to mutant IL-4Rα compared to the binding of the control (0.04 OD and 0.05 OD, respectively). 450 and 0.14OD 450 In addition, substitution of amino acid residue D125, located near amino acid residue D66 on the crystal structure of IL-4Rα, with arginine (see Figure 2) also reduced the IL-4Rα signaling activity by 0.59 OD 450 The remaining amino acid substitutions were either within the range of positive binding or outside the defined structural epitope.

[0127] [Table 6]

[0128] Example 2c. Structural epitope of Ab1 Fab by X-ray crystallography. The physical epitope of the Fab of Ab1 anti-human IL-4Rα antibody on human IL-4Rα was determined essentially as described above. Crystals were obtained and X-ray diffraction data were collected at the Advanced Photon Source. The diffraction data were reduced and analyzed by molecular replacement and refined to obtain a 2.49 angstrom structure of the exemplary Fab complexed with IL-4Rα ECD. From the resulting crystal structure, any IL-4Rα amino acid residue within 4.5 angstroms of an atom of the co-crystallized Fab was counted as part of the epitope (using Molecular Operating Environment (MOE) visualization, modeling and simulation software [Chemical Computing Group], Coot (General Public License) and PyMOL visualization software [Schrodinger®]).

[0129] MOE, Coot, and PyMOL analyses demonstrated that IL-4Rα amino acid residues (within 4.5 angstroms of the exemplified Fab in the crystal structure complex, relative to SEQ ID NO: 15) comprise a structural epitope. Specifically, the analyses determined that the structural epitope comprises the following amino acid residues: Asp at position 12, Met at position 14, Ser at position 15, Ile at position 16, Leu at position 39, Phe at position 41, Leu at position 42, Thr at position 48, Cys at position 49, Ile at position 50, Glu at position 52, His at position 62, Leu at position 64, Met at position 65, Asp at position 66, Asp at position 67, Val at position 68, Val at position 69, Asp at position 72, Arg at position 99, Pro at position 121, Pro at position 123, Pro at position 124, Asp at position 125, and Pro at position 192. Asp at position 66 was well-balanced with the heavy chain of Ab1Fab, interacting between 2.6 and 2.9 Å. Asp at position 67 had a longer range of interactions between 3.1-3.5 Å and showed flexibility in its binding position as evidenced by the observation of excess density around its side chain. Analysis determined that the structural epitope spans domains 1 and 2 of the N-terminal fibronectin type III domain of IL-4Rα. Furthermore, analysis determined that the following amino acid residues of the structural epitope are located in domain 2 of the N-terminal fibronectin type III domain of IL-4Rα: R99, P121, P123, P124, D125, P192.

[0130] An overlay of the illustrated anti-human IL-4Rα Ab1 Fab with the crystal structure of dupilumab Fab with a crystal kappa design complexed with human IL-4Rα (pdb accession code 6WGL) showed that anti-human IL-4Rα Ab1 binds to a novel epitope on IL-4Rα when compared to dupilumab ( FIG. 3 ).

[0131] Alignment (using PyMOL visualization software) of the exemplified anti-human IL-4Rα Ab1 Fab:IL-4Rα complex crystal structure with the published complexes of IL-4 and IL-13 on IL-4Rα and their respective receptors (pdb accession codes 3BPN and 3BPO) in each structure showed that the exemplified anti-human IL-4Rα Ab Fab antibody epitope overlaps with both the IL-4 and IL-13 binding sites on IL-4Rα, indicating that binding of the exemplified Ab1 physically blocks the binding of IL-4 and IL-13 cytokines to IL-4Rα.

[0132] Example 2d. Functional epitope of Ab1. The functional epitope of the exemplified human IL-4Rα antibody Ab1 was determined by ELISA. Briefly, 30 surface amino acid residue substitutions were individually introduced into the hexahistidine-tagged human IL-4Rα extracellular domain (ECD) as follows: K2D, E6R, K22D, P26R, T31R, F41A, L42G, L43G, E45R, E52R, G56R, D66R, A71R, Q82G, K87D, E94R, H107A, D108R, P124R, D125R, D143R, R148D, L155R, R160D, S164R, S168R, Q181R, P192R, K195D, or H197G. Each mutein with a single amino acid residue substitution as described above was transiently expressed in CHO cells and purified using standard immobilized metal affinity chromatography techniques. ELISA plates were coated with 1 μg / mL goat anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories, Cat. No. 109-005-098) in PBS overnight at 4° C., then washed 3 times with PBST and blocked with PBS-casein for 1 hour at room temperature. Plates were then washed 3 times with PBST, and the exemplified human IL-4Rα antibody was added to the wells at a final concentration of 1 μg / mL in PBS-casein and incubated for 1 hour at room temperature. Plates were washed 3 times with PBST, and IL-4Rα muteins were serially diluted 5-fold from 1 μg / mL in PBS-casein in triplicate, added to the plate at 50 μL / well and incubated for 1 hour at room temperature. Plates were washed 3 times with PBST and a 1000-fold dilution of anti-histidine tag antibody HRP conjugate (R&D Systems, Cat. No. MAB050H) in PBS-casein was added and incubated for 45 minutes at room temperature. Plates were washed 3 times and TMB substrate (Pierce, Cat. No. 34028) was added according to the manufacturer's instructions, the reaction was quenched with H2SO4 and absorbance was read at 450 nm in an ELISA plate reader. The functional epitope of the antibody was determined as the mutated amino acid residue corresponding to wells that showed no binding signal or a significantly reduced binding signal compared to the wild-type control.

[0133] The results in Table 6B show that the functional epitope of the exemplified anti-human IL-4Rα antibody Ab1 includes amino acid residue D66. Substitution of the amino acid residue D66 to D66R on IL-4Rα reduced binding of Ab1 to D66R IL-4Rα compared to the binding of the negative control (0.047 OD 450 and 0.063OD 450 ). Amino acid residue D66 is located near the structural epitope residues D67 and D125 in the crystal structure of IL-4Rα (FIG. 4). The remaining amino acid substitutions were either within the range of positive binding or outside the determined structural epitope.

[0134] [Table 7]

[0135] Example 3. Binding potency of exemplary anti-human IL-4Rα antibodies and the IL-4RαAb1GC conjugate of Example 1b Example 3a. Elisa Binding: A competitive Meso Scale Discovery (MSD) ELISA binding assay was used to measure the binding potency of exemplary anti-human IL-4Rα Ab1 and IL-4Rα Ab1GC conjugates to human and cynomolgus IL-4Rα. A constant final concentration of Ab1 or conjugate (10 pM) was mixed with a 3-fold dilution series of human or cynomolgus IL-4Rα to obtain a final starting concentration of 10 nM, and the mixtures were incubated at 37° C. for 4 days. A 96-well multi-array plate (Meso Scale Diagnostics, Cat. No. L15XA-3) was coated overnight at 4° C. with 0.5 μg / mL hexahistidine-tagged human or cynomolgus IL-4Rα ECD in phosphate-buffered saline (PBS). After coating, plates were washed 10 times with 200 μL PBST (PBS with 0.05% Tween® 20) and blocked with 300 μL PBS Casein Blocking Buffer (Pierce, Cat. No. 37528) for 1 hour at 37° C. Plates were then washed 10 times as above and 50 μL of the pre-incubated antibody:IL-4Rα dilution series was transferred to the wells and incubated for 150 seconds at 37° C. with shaking at 300 rpm. Plates were washed 10 times with PBST and 50 μL of 1 μg / mL anti-human antibody sulfo-tag20 (Meso Scale Diagnostics, Catalog No. R32AJ-1) was added to the plate for the assays in Table 7a and anti-human NHP kappa light chain SULFO-TAG20 (Meso Scale Diagnostics, Catalog No. D20TF-6) was added to the plate for the assays in Table 7b and the plate was incubated at 37° C. for 30 minutes with shaking at 300 rpm. Plates were washed 10 times with PBST and 150 μL / well of 1× Read Buffer T was added to the wells and analyzed on a SECTOR® Imager 6000 (Meso Scale Diagnostics) 15 minutes after buffer addition. Apparent K Dis determined by fitting a sigmoidal curve to the electrochemiluminescence (ECL) response versus log(soluble IL-4Rα concentration) using GraphPad Prism9. Data are graphed with normalized ECL values. Results in Table 7a are representative data from an individual experiment, and results in Table 7b are representative data from the average of three independent experiments performed in duplicate.

[0136] The exemplary results in Tables 7a and 7b show that the exemplary anti-IL-4Rα antibodies and Ab1GC conjugates have comparable K D The results show that IL-4Rα binds to both human and cynomolgus monkey IL-4Rα.

[0137] [Table 8]

[0138] [Table 9]

[0139] Example 3b. Binding to B and T cells: Binding of the exemplary anti-human IL-4Rα antibodies to B and T cells was tested in a fluorescence-activated cell sorting (FACS) assay. Human PBMCs were isolated from human blood samples by standard Ficoll-Paque™ plus (GE HEALTHCARE) density gradient centrifugation. Freshly isolated PBMCs were cultured at 2×10 6Cells were resuspended at 100 μL / mL, left at room temperature for 15 min, then plated at 100 μL / well into a round-bottom 96-well plate (COSTAR®) and washed with FACS buffer (PBS containing 2% fetal bovine serum from Corning®). The exemplified anti-human IL-4Rα antibody and respective control IgG antibody conjugated to Alexa Fluor® 647 were added to the wells at 66.67 nM and diluted 4-fold in duplicate according to the manufacturer's protocol (Thermo Fisher Scientific). An equal volume of 2× antibody cocktail containing human TruStain FcX™, FITC anti-human CD3 antibody, Alexa Fluor® 700 anti-human CD4 antibody (all from Biolegend®) and CD20 monoclonal antibody (2H7), PerCP-Cyanine5.5 (Thermo Fisher Scientific) was then added to the wells. Cells were incubated for 30 min at 4°C, washed twice with FACS buffer, and resuspended in a final volume of 100 μL FACS buffer. Viability dye, Sytox™ blue (Thermo Fisher Scientific), was added and samples were analyzed via a flow cytometer (LSRFortessa™ X-20; BD BIOSCIENCES). Data analysis was performed using FlowJo software and statistical analysis was performed using GraphPad Prism9. Data represent the mean ± SEM of the percentage of IL-4Rα expressing cells from CD20 B cell and CD4 positive T cell populations from six donors. Curves were generated by fitting sigmoidal curves of log(Ab concentration) vs. percent of positive IL-4Rα expressing cells from individual cell populations.

[0140] Results in Table 8A from a representative experiment show that the exemplified anti-human IL-4Rα Ab1 and Ab7 inhibited human PBMC-isolated B cells (EC of 0.15 nM and 0.14 nM, respectively). 50 ) and CD4 + T cells (EC of 26.3 nM and 28.7 nM, respectively) 50 ) with comparable affinity to IL-4Rα.

[0141] Furthermore, results in Table 8B from a representative experiment comparing the exemplified effector-null anti-human IL-4Rα Ab8 to Ab7 show that effector-null Ab8 inhibited Ab7 (EC of 0.27 nM). 50 ) compared to IgG1, which showed an unexpectedly decreased affinity for B cells (EC 50 ), indicating that the Fc portion of an antibody can affect the binding of the exemplified IL-4Rα antibody to B cells. Both Ab7 and Ab8 share the same CDR amino acid sequence.

[0142] [Table 10]

[0143] [Table 11]

[0144] Example 4. In vitro functional characterization of anti-human IL-4Rα AbGC conjugates Example 4a. Cell-based IL-4 and IL-13 cytokine blocking activity by anti-human IL-4Rα Ab1: Antagonistic activity of exemplary anti-human IL-4Rα antibodies against IL-4 and IL-13 was performed using the HEK-Blue IL-4R and IL-13R expressing cell line (InvivoGen) by measuring secreted embryonic alkaline phosphatase (SEAP) activity. HEK-Blue cells were plated at 5×10 in 50 μL of growth medium in polylysine-coated plates. 4Cells / well were seeded overnight. Anti-human IL-4Rα antibody was prepared in Greiner 96-well low protein binding plates in 4-fold dilutions starting at 20 μg / mL in growth medium. The dilution series was mixed with an equal amount of either recombinant human IL-4 or IL-13 (Eli Lilly) in growth medium. 50 μL of the mixture was then added to the plate with HEK-Blue cells to give a final concentration of 100 pg / mL human IL-4 or 10 ng / mL human IL-13, and the plate was then incubated overnight at 37° C. in a tissue culture incubator. 20 μL of supernatant from the overnight incubated plate was transferred to a 96-well tissue culture treated plate, 180 μL of QUANTI-Blue™ (InvivoGen) was added per well, and the mixture was incubated at 37° C. for 45 minutes. Secreted embryonic alkaline phosphatase (SEAP) activity was measured at 650 nm in a SpectraMax microplate reader (Molecular Devices). Results were reported as optical density (OD) at 650 nm and statistical analysis was performed using GraphPad Prism9. IC 50 and curves were generated by fitting a sigmoidal curve of log(Ab concentration) vs. OD at 650 nm for each example antibody.

[0145] The results show that the exemplary anti-human IL-4Rα antibodies Ab1, Ab7, and Ab9 inhibited both IL-4 and IL-13 induced SEAP activity in a dose-dependent manner, with IC of 0.08 nM, 0.07 nM, and 0.03 nM for IL-4 inhibition, respectively. 50 with IC's of 0.67 nM, 0.51 nM, and 0.24 nM, respectively, for IL-13 inhibition. 50 It was shown that the above-mentioned

[0146] [Table 12]

[0147] Example 4b. Internalization of anti-human IL-4Rα Ab1GC conjugate: The ability of the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b to bind to IL-4Rα and internalize into Daudi cells was evaluated. The pH-sensitive label pHrodo™ ifL Microscale Labeling Kit (Invitrogen #P36014) was used to label 100 μg of F(ab')2 goat anti-human IgG Fcγ (Jackson Immuno Research Labs #109-006-098) according to the manufacturer's protocol. Daudi cells (ATCC #CCL-213) were cultured at 1×10 6 The cells were resuspended at 100 μL / mL and 100 μL was seeded into a 96-well plate. The exemplary anti-human IL-4Rα Ab1GC conjugate and anti-human IL-4Rα Ab were incubated with equal concentrations of pHrodo-labeled F(ab')2 goat anti-human IgG for complex formation at 4°C for 30 minutes, then serially diluted 10-fold for a three-point curve, added to Daudi cells, and incubated at 37°C in a CO2 incubator for 25 hours. After incubation, the plate was spun down at 400×g for 3 minutes and the supernatant was aspirated. An antibody cocktail containing CD20 monoclonal antibody (2H7), PerCP-Cyanine 5.5 (eBioscience™) and human TruStain FcX™ (BioLegend) in d-PBS with 2% fetal bovine serum was added to the wells and mixed by pipetting. The stained cells were then incubated at 4°C for 30 minutes. Cells were then washed 2-3 times with 100-150 μL d-PBS containing 2% FBS. Cells were resuspended in 100 μL d-PBS containing 2% FBS and 5 μL SYTOX™ Blue Dead Cell Stain (Invitrogen) was added to appropriate wells and mixed by pipetting. Plates were analyzed on a BD LSRFortessa™ X-20 Cell Analyzer. Analysis was performed using FlowJo software. Curves were generated by plotting concentration vs. pHrodo geometric mean fluorescence intensity (gMFI) using GraphPad Prism9.

[0148] The results in Table 10 show that the anti-human IL-4Rα Ab1 GC conjugate of Example 1b bound and internalized in Daudi cells in a dose-dependent manner with MFIs of 859, 509, and 397 at 10, 1, and 0.1 μg / mL, respectively. The internalization of the anti-human IL-4Rα Ab1 GC conjugate was comparable to that of unconjugated Ab1, indicating that the anti-human IL-4Rα Ab1 GC conjugate binding and internalization functions were not affected by the conjugation of anti-human IL-4Rα Ab1 to glucocorticoids.

[0149] [Table 13]

[0150] Inhibition of IL-4 and IL-13-induced pSTAT6 phosphorylation in human PBMCs: Inhibition of IL-4 and IL-13-mediated IL-4R pSTAT6 phosphorylation by the exemplary anti-human IL-4RαAb1GC conjugates and anti-human IL-4RαAb1 of Example 1b was evaluated in primary B and / or T cells. Human PBMCs were isolated from human blood samples by standard Ficoll-Paque™ plus (GE HEALTHCARE) density gradient centrifugation. The isolated cells were resuspended at 100-300 million cells in 100 mL complete medium (10% FBS, 1% penicillin-streptomycin solution, from Corning®, and 1% GlutaMAX™ and 0.1% β-mercaptoethanol, RPMI-1640, from Gibco™) in a T175 flask (FALCON) and stimulated overnight with 2 μg / mL PHA (SIGMA), 0.5 μg / mL LPS (SIGMA) and 100 ng / mL recombinant human IL-6. The cells were washed with fresh medium and plated at 5×10 cells / well in a 96-well round bottom plate (Corning®) in 100 μL complete medium containing 10 μg / mL of an exemplary antibody diluted in 4-fold dilutions and 11-point titrations. 4 ~2×10 5Cells were seeded at 100 μL / well. Cells were incubated with samples for 30 min at room temperature and then stimulated with human recombinant IL-4 (final concentration 20 ng / mL) or human recombinant IL-13 (final concentration 100 ng / mL, R&D SYSTEMS) for 12 min at room temperature. Stimulation was stopped by adding 120 μL of 1X Lyse / Fix Buffer (BD BIOSCIENCES) for 5 min, then the plate was centrifuged at 2000 rpm for 2 min and the supernatant was aspirated. The cell pellet was resuspended in 100 μL of ice-cold methanol (SIGMA), placed on ice for 20 min and washed with DPBS containing 2% FBS (Corning®). Cells were resuspended in 50 μL of antibody cocktail against the following proteins: CD4, CD33, CD8, and CD3 (Thermo Fisher Scientific), phosphorylated STAT6 (Biolegend®), and CD20 (BD BIOSCIENCES), incubated for 30 minutes at room temperature, and then washed with DPBS containing 2% FBS. Cell samples were analyzed using a flow cytometer. Analysis was performed using FlowJo software and statistical analysis was performed using GraphPad Prism9. Curves were generated by fitting sigmoidal curves of log(Ab concentration) vs. percent inhibition of phosphorylated STAT6 for each individual donor cell population (n=2).

[0151] The results in Table 11A show that the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b inhibited IL-4-induced STAT6 phosphorylation in CD4+ T cells (IC of 0.017 μg / mL). 50 ) and B cells (IC of 0.041 μg / mL) 50 ) in a dose-dependent manner.

[0152] The results in Table 11B show that the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b dose-dependently inhibited IL-13-induced STAT6 phosphorylation in B cells (IC of 0.064 μg / mL). 50) demonstrating the ability of the human IL-4Rα Ab1GC conjugate to block both IL-4 and IL-13 signaling through the IL-4R.

[0153] [Table 14]

[0154] [Table 15]

[0155] Example 4d. Inhibition of IL-4-induced B cell proliferation: Inhibition of B cell proliferation by the illustrated anti-human IL-4Rα Ab1GC conjugate of Example 1b and anti-human IL-4Rα Ab1 and Ab7 was evaluated in primary B cells isolated from human PBMCs. Human PBMCs were isolated from human blood samples by standard Ficoll-Paque™ plus (GE HEALTHCARE) density gradient centrifugation, and primary B cells were isolated from the PBMC suspension by negative selection using the EasySep™ human naive B cell enrichment kit according to the manufacturer's protocol (STEMCELL™ technology). 1×10 isolated human primary B cells were cultured at 1×10 6 The cells were resuspended at 100 cells / mL and plated in polystyrene 96-well U-bottom plates in complete medium (RPMI-1640 with 10% fetal bovine serum, 1×MEM-non-essential amino acids, 1 mM sodium pyruvate, 1× penicillin-streptomycin solution (all from Corning®) and 1× GlutaMAX™ (Gibco™), 0.1% β-mercaptoethanol (LIFE TECHNOLOGIES). Cells were pretreated with anti-human IL-4Rα Ab1GC conjugate, anti-human IL-4Rα Ab1 and Ab7.

[0156] (6aR,6bS,7S,8aS,8bS,10S,11aR,12aS,12bS)-10-(3-((3-aminobenzyl)oxy)-2-fluoro-6-vinylphenyl)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (compound of Preparation 6, also referred to herein as "GC1"), or an isotype control, was titrated in a 10-point series of 4 dilutions at 66.67 nM for 0.5 to 1 hour. The cells were stimulated with human CD40 / TNFRSF5 antibody (200 ng / mL; R&D SYSTEMS) and IL-4 recombinant human protein (5 ng / mL; R&D SYSTEMS) at 37° C. and 5% CO 2 for 2 days. The cells were then incubated at 4° C. for 2 h at 4° C. for 1 h at 4° C. for 2 ... 3 3H]-thymidine (1 mCi thymidine / well; PerkinElmer®) for 18 hours at 37°C. 3 Levels of [H]-thymidine incorporation were measured by a microplate counter (MicroBeta2; PerkinElmer®) and expressed as cell counts per minute (CCPM). Statistical analysis was performed using GraphPad Prism9, and curves were generated by fitting sigmoidal curves of log(Ab concentration) versus mean percent inhibition of CCPM compared to CD40 stimulation alone from two donors.

[0157] The results in Table 12A show that the exemplary anti-human IL-4Rα Ab1 GC conjugate of Example 1b is more potent than unconjugated anti-human IL-4Rα Ab1 (IC of 1.31 nM). 50 ) comparable to IL-4-induced B cell proliferation (IC of 1.41 nM) 50 ) in a dose-dependent manner. GC1 alone was comparable to the isotype control, i.e., no significant inhibition was observed.

[0158] Table 12B shows representative results of inhibition of IL-4-induced B cell proliferation by anti-human IL-4Rα Ab1 and Ab7.

[0159] [Table 16]

[0160] [Table 17]

[0161] Example 4e. Glucocorticoid receptor-mediated inhibition of anti-CD40-induced B cell proliferation: Inhibition of B cell proliferation by the anti-human IL-4RαAb1GC conjugates and anti-human IL-4RαAb1 exemplified in Example 1b was evaluated in primary B cells isolated from human PBMCs. Human PBMCs were isolated from human blood samples by standard Ficoll-Paque™ plus (GE HEALTHCARE) density gradient centrifugation, and primary B cells were isolated from the PBMC suspension by negative selection using the EasySep™ human naive B cell enrichment kit according to the manufacturer's protocol (STEMCELL™ technology). 1×10 isolated human primary B cells were cultured at 1×10 6 The cells were resuspended at 1000 cells / mL and seeded in polystyrene 96-well U-bottom plates in complete medium (RPMI-1640 with 10% fetal bovine serum, 1x MEM-non-essential amino acids, 1 mM sodium pyruvate, 1x penicillin-streptomycin solution (all from Corning®) and 1x GlutaMAX™ (Gibco™), 0.1% β-mercaptoethanol (LIFE TECHNOLOGIES). Cells were pretreated for 0.5-1 hour with 100 nM 4-fold diluted anti-human IL-4Rα Ab1, anti-human IL-4Rα Ab1 GC conjugate, compound of Preparation 6 (GC1) or isotype control in a 9-point titration. Cells were stimulated with human CD40 / TNFRSF5 antibody (200 ng / mL; R&D SYSTEMS) for 2 days at 37°C and 5% CO2. Cells were then incubated at 4°C for 2 h at 37°C for 1 h at 4°C for 2 ... 3 3H]-thymidine (1 mCi thymidine / well; PerkinElmer®) for 18 hours at 37°C. 3Levels of [H]-thymidine incorporation were measured by a microplate counter (MicroBeta2; PerkinElmer®) and expressed as cell counts per minute (CCPM). Statistical analysis was performed using GraphPad Prism9, and curves were generated by fitting sigmoidal curves of log(Ab concentration) versus mean percent inhibition of CCPM compared to no stimulation from two donors.

[0162] The results in Table 13 and FIG. 5 show that the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b and GC1 alone dose-dependently inhibited anti-CD40-induced B cell proliferation (IC of 5.51 nM and 3.73 nM, respectively). 50 ). Minimal inhibition was observed with anti-human IL-4Rα Ab1, which was comparable to the isotype alone. This indicates that the GC in the anti-human IL-4Rα Ab1 GC conjugate is effectively delivered to B cells and effectively modulates GC receptor agonism in B cells to inhibit B cell proliferation independently of IL-4R-mediated inhibition of B cell proliferation.

[0163] [Table 18]

[0164] Example 4f. Inhibition of IL-4-induced CD23 and induction of CD163 expression in bone marrow cells: Inhibition of IL-4-induced CD23 expression and induction of glucocorticoid-induced CD163 expression by the exemplary anti-human IL-4RαAb1GC conjugate of Example 1b was evaluated in bone marrow cells. CD163 is expressed by monocytic cells and is associated with autoimmune disorders. Glucocorticoids have been shown to induce CD163 expression, which is believed to contribute to the anti-inflammatory effect of glucocorticoids. To determine the effect of glucocorticoids on anti-human IL-4RαAb1GC conjugates, CD163 expression levels on the surface of monocytic cells in response to treatment with anti-human IL-4RαAb1GC conjugates are evaluated.

[0165] Briefly, fresh LRS-WBC donors are obtained from the San Diego Blood Bank for PBMC isolation by standard Ficoll-Paque™ plus (GE HEALTHCARE) density gradient centrifugation. Cells are plated at 2×10 in 96-well flat-bottom plates. 5 Cells / well were seeded. 50 μL of 3× serially diluted antibodies were added to the wells and incubated at 37° C., 5% CO2 for 30 minutes. Then 50 μL of 3× stimulation recombinant human IL-4 (R&D SYSTEMS) in complete medium was added to the wells to a final concentration of 10 ng / mL. The plates were incubated at 37° C., 5% CO2 for 48 hours, and the cells were washed and resuspended in FACS buffer containing Human TruStain FcX™, Brilliant Violet 605™ anti-human CD163 antibody, Brilliant Violet 785™ anti-human CD33 antibody, FITC anti-human CD3 antibody (from Biolegend®), CD20 monoclonal antibody (2H7) PerCP-Cyanine5.5, and CD23 monoclonal antibody (EBVCS2), APC (from THERMO FISHER SCIENTIFIC). Cells were incubated for 30 min at 4° C., washed twice with FACS buffer, and resuspended in a final volume of 100 μL FACS buffer. Viability dye, Sytox™ blue (THERMO FISHER SCIENTIFIC), was added to the wells, and samples were analyzed by flow cytometer (LSRFortessa™ X-20; BDBIOSCIENCES). Data analysis was performed using FlowJo software. Myeloid cells were identified as Sytox™ blue, CD3, and CD20 negative, CD33 positive cells. Data are presented as sigmoidal curve fits of myeloid cell geometric mean fluorescence intensity (gMFI) versus log(Ab concentration) (mean ± SD) of 3 or 4 donors, and statistical analysis is performed using GraphPad Prism9.

[0166] The results in Table 14 and Figures 6A and 6B show that the exemplary anti-human IL-4Rα Ab1GC conjugate and anti-human IL-4Rα Ab1 of Example 1b had IC 50 6A) inhibited IL-4 (FIG. 6A)-induced CD23 expression on bone marrow cells. Furthermore, the results showed that the anti-human IL-4Rα Ab1GC conjugate significantly increased CD163 expression at 1000 nM, 250 nM, and 63 nM (gMFI of 8462, 5984, and 2317, respectively) compared to the unconjugated Ab1 at 1000 nM (gMFI of 941) (FIG. 6B). This indicates that the exemplified anti-human IL-4Rα Ab1GC conjugate can inhibit the IL4R-mediated response mediated by Ab1 and induce the GC receptor-mediated response in the same cells, demonstrating the dual functionality of the anti-human IL-4Rα Ab1GC conjugate from antibody and glucocorticoid, as well as the effective delivery of GC to cells by antibody.

[0167] [Table 19]

[0168] Example 4g. Induction of glucocorticoid-inducible gene expression in Th2 differentiated T cells: Induction and expression of three glucocorticoid receptor-mediated genes (Tsc22d3, Fkbp5, and Zbtb16) and one cytokine is measured in primary human T cells differentiated ex vivo to a Th2 phenotype representative of cells involved in type 2 inflammation and disease.

[0169] Human Th2 cells were differentiated in vitro by culturing purified naive CD4 T cells with anti-human CD3 (BioXCell#BE0001-2), anti-human CD28 (BioLegend#302934), anti-human IFNγ (R&D Systems#MAB285-500), recombinant human IL-2 (R&D Systems#202-IL-050 / CF), and recombinant human IL-4 (R&D Systems#6507-IL-100 / CF) for 14 days. Terminally differentiated Th2 cells were then rested without IL-4 for 12 hours prior to assay to restore IL-4R surface expression. Flow cytometry staining was used to assess cell purity on a BD LSRFortessa Cell Analyzer. Th2 cells were identified with CD4+ (anti-human CD4-eFluor-450, Fisher Scientific #48-0047-42), GATA3+ (anti-human GATA3-PerCP / Cyanine5.5, BioLegend #653812), and IL4R+ (anti-IL-4Rα antibody-Alexa Fluor-647, Lilly). 6 Th2 cells / well were treated with 100 nM IL4R-GC Ab1 and stimulated with human T activator CD3 / CD28 Dynabeads (Fisher Scientific #11132D) for 24 hours at 37°C. Cells from each assay condition were lysed in RLT buffer (Qiagen #79216) and frozen at -80°C. RNA was then isolated using the Rneasy 96 Kit (Qiagen #74181) according to the manufacturer's protocol. Data are representative of four technical replicates per assay condition (n=4).

[0170] Gene expression levels were determined using the NanoString platform with a custom gene panel (Table 15) according to the manufacturer's recommended protocol. RNA isolated from in vitro cultures was analyzed by OD spectrometry on a Cytation5 (Biotek) platform. 260Measurements were used to quantify expression of the RNA. RNA was diluted to 20ng / μl in Rnase-free water and a total of 100ng (in 5μl) was used to prepare the NanoString cartridges. Raw mRNA counts were normalized using nSolver Advanced Analysis software (version 2.0.115) according to the manufacturer's recommended data processing methods. All mRNA counts were first scaled to within-sample binding density controls, then experimental genes were further normalized to housekeeping gene indices, followed by dynamic housekeeping gene selection for the entire data set to minimize housekeeper variance. Normalized gene counts were converted to Log2 scale, and the relative expression of experimental treatment groups was determined by subtracting the mean Log2 expression of the "no treatment" group. Statistical analysis was performed using GraphPad Prism9. Results are reported as the mean log2 expression for each gene within the treatment group + SD, normalized to the mean of the replicates of the non-treated group for each replicate (n=4 for all groups). Differences are assessed using two-way analysis of variance (ANOVA) on normalized values, and comparisons to the untreated group are assessed at a significance level of p<0.001 using Bonferroni correction for multiple comparisons.

[0171] The results in Table 16 show that the anti-human IL-4RαAb1GC conjugate of Example 1b induced the mRNA expression of glucocorticoid receptor-mediated genes Tsc22d3 (2.96-fold increase, p-value < 0.001), Fkbp5 (1.81-fold increase, p-value < 0.001), Zbtb16 (1.29-fold increase, p-value < 0.003) in Th2-differentiated T cells, and reduced the mRNA expression of the cytokine IL-5 by 2.29-fold (p-value < 0.0001). This indicates that the anti-human IL4RαAb1GC conjugate can induce GC / GR-mediated gene regulation and reduce IL-5 expression in cells representative of cells involved in type 2 inflammation and disease.

[0172] [Table 20]

[0173] [Table 21]

[0174] Example 4h. Inhibition of Cytokine Secretion from Human PBMC: PBMCs were isolated from Ficoll-layered blood centrifuged at 400×g for 30 min at room temperature. The PBMC layer was washed with sterile RPMI-1640 medium (Corning® Catalog No. 10041CV) and centrifuged at 1500 rpm for 5 min at 4° C. Red blood cells are lysed by resuspending the cell pellet in 5 mL of ACK Lysis Buffer (GIBCO Catalog No. A1049201) and incubating at room temperature for 5 min. After RBC lysis, cells were washed and cultured at 1×10 in warmed complete medium (RPMI-1640 with 10% FBS, 1% MEM Non-Essential Amino Acids Solution, 1% Penicillin-Streptomycin Solution, Corning® Solution, and 1% GlutaMAX™ and 0.1% β-mercaptoethanol from Gibco™). 6 Wash and resuspend cells at 1 x 10 cells / mL. 6Cells / well are seeded in 96-well flat-bottom plates. 50 μL of 4× control IgG, anti-human IL4Rα Ab1, anti-human IL4Rα Ab1 GC conjugate of Example 1b, or GC1 alone (3-fold serial dilutions of final concentration 100 nM for a 9-point curve) are added to the wells. 50 μL of 4× stimulation cocktail consisting of 40 μg / mL PHA-M (phytohemagglutinin, M-type; LIFE TECHNOLOGIES) and 400 ng / mL PMA (phorbol 12-myristate 13-acetate; TOCRIS) in complete medium are then added to the wells. The plates are incubated for 48 hours at 37° C., 5% CO2. After the incubation period, the plates are centrifuged at 2000 rpm for 1 minute, and the top 100 μL of the supernatant is removed and stored at −80° C. until ready for cytokine detection. Cytokine release is detected using the U-PLEX Custom Biomarker [Human] Multiplex Assay (MESO SCALE DISCOVERY) according to the manufacturer's protocol. Statistical analysis is performed using GraphPad Prism9. Data are presented as sigmoidal curve fits of the mean percent inhibition of individual donors for each cytokine (n=2) versus log(Ab concentration) and statistical analysis is performed using GraphPad Prism9.

[0175] The results in Table 17 and Figures 7A-C show that the anti-human IL-4Rα Ab1 GC conjugate of Example 1b significantly inhibited both IL-4R-mediated and glucocorticoid receptor-mediated cytokine secretion. The anti-human IL-4Rα Ab1 GC conjugate inhibited MDC secretion similarly to anti-human IL-4Rα Ab1 (79.7% and 74.7% at 100 nM, respectively). The anti-human IL-4Rα Ab1 GC conjugate inhibited GM-CSF secretion more reliably than Ab1 alone (77.6% and 40.9% at 100 nM, respectively, Figure 4B). Furthermore, the anti-human IL-4Rα Ab1 GC conjugate and GC1 payload inhibited IL-5 secretion by 78.5% and 97.4% at 100 nM, respectively (Figure 4C), while Ab1 had no effect (approximately 13.3% at 100 nM). This data demonstrates the dual functionality of the anti-human IL-4Rα Ab1GC conjugate in inhibiting both IL-4R-dependent and IL-4R-independent cytokine secretion, demonstrating the additional functionality and improved efficacy of the anti-human IL-4Rα Ab1GC conjugate in cytokine inhibition when compared to the antibody alone.

[0176] [Table 22]

[0177] Example 5. Effector Function and Fcγ Receptor Binding of the Exemplary Anti-Human IL-4Rα Antibody GC Conjugate of Example 1b Example 5a. Human Fcγ Receptor Binding. The binding affinity of the exemplary anti-IL-4Rα GC conjugate and anti-human IL-4Rα antibody of Example 1b to human Fcγ receptors was evaluated by surface plasmon resonance (SPR) analysis. Series S CM5 chips (Cytiva P / N BR100530) were prepared using the manufacturer's EDC / NHS amine coupling method (Cytiva P / N BR100050). Briefly, the surfaces of all four flow cells (FCs) were activated by injecting a 1:1 mixture of EDC / NHS at 10 μL / min for 7 min. Protein A (Calbiochem P / N 539202) was diluted to 100 μg / mL in 10 mM acetate buffer, pH 4.5, and immobilized to approximately 4000 RU on all four FCs by injection at a flow rate of 10 μL / min for 7 min. Unreacted sites were blocked by injection of ethanolamine at 10 μL / min for 7 min. Non-covalently associated proteins were removed using 2×10 μL injections of glycine at pH 1.5. The running buffer was 1×HBS-EP+ (TEKNOVA, P / N H8022). FcγR extracellular domains (ECD)-FcγRI (CD64), FcγRIIA_131R, and FcγRIIA_131H (CD32a), FcγRIIIA_158V, FcγRIIIA_158F (CD16a), and FcγRIIb (CD32b) were produced from stable CHO cell expression and purified using IgG Sepharose and size exclusion chromatography. For FcγRI binding, antibodies were diluted to 2.5 μg / mL in running buffer and approximately 150 RU of each antibody was captured with FC2-4 (RU capture). FC1 was the reference FC, so no antibody was captured by FC1. FcγRI ECD was diluted to 200 nM in running buffer and then serially diluted 2-fold in running buffer to 0.78 nM. Duplicate injections of each concentration were injected into all FCs at 40 μL / min for 120 s, followed by a dissociation phase of 1200 s. Regeneration was performed by injecting 15 μL of 10 mM glycine, pH 1.5 at 30 μL / min into all FCs. Reference subtraction data were collected for FC2 FC1, FC3-FC1, and FC4-FC1, and measurements were taken at 25° C. Affinity (K D) were calculated using either steady-state equilibrium analysis or the "1:1 (Langmuir) binding" model of BIA evaluation using Scrubber2 Biacore evaluation software. For FcγRIIa, FcγRIIb, and FcγRIIIa binding, antibodies were diluted to 5 μg / mL in running buffer and approximately 500 RU of each antibody was captured in FC2-4). FC1 was the reference FC. Fcγ receptor ECD was diluted to 10 μM in running buffer and then serially diluted 2-fold in running buffer to 39 nM. Duplicate injections of each concentration were injected into all FCs at 40 μL / min for 60 s, followed by a dissociation phase of 120 s. Regeneration was performed by injecting 15 μL of 10 mM glycine, pH 1.5, into all FCs at 30 μL / min. Reference subtracted data were collected for FC2-FC1, FC3-FC1, and FC4-FC1, and measurements were taken at 25°C. Affinity (K D ) was calculated using steady-state equilibrium analysis with Scrubber2 Biacore® evaluation software. Each receptor was assayed at least twice.

[0178] The results in Table 18A show the binding affinity (K D ) is shown.

[0179] The results in Table 18B show the binding affinity (K D ) is summarized below.

[0180] [Table 23]

[0181] [Table 24]

[0182] Example 5b. Antibody-Dependent Cellular Cytotoxicity (ADCC): In vitro ADCC assay of the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b was evaluated in a reporter gene-based ADCC assay. Briefly, Daudi cells (ATCC, #CCL-213) expressing human IL-4Rα and human CD20 were used as the target cell line, and Jurkat cells (Eli Lilly and Company) expressing functional FcγRIIIa(V158)-NFAT-Luc were used as the effector cell line. All test molecules and cells were diluted in assay medium containing RPMI-1640 (without phenol red) with 0.1 mM non-essential amino acids (NEAA), 1 mM sodium pyruvate, 2 mM L-glutamine, 500 U / mL penicillin-streptomycin, and 0.1% w / v BSA. Test antibodies were first diluted to a 3x concentration of 30 nM and then serially diluted 7 times at a 1:4 ratio. 50 μL / well of each molecule was dispensed in triplicate into white opaque bottom 96-well plates (Costar, #3917). CD20 antibody was used as a positive control. Daudi target cells were then plated at 5x10 in 50 μL aliquots. 4 1.5 × 10 cells / well were added to the plate and incubated for 1 h at 37 °C. Jurkat V158 cells were then added to the wells at 1.5 × 10 cells / well in 50 μL aliquots. 5 Cells / well were added and incubated at 37°C for 4 hours followed by addition of 100 μL / well of One-Glo luciferase substrate (Promega, #E8130). Plate contents were mixed using a plate shaker at low speed, incubated at room temperature for 5 minutes, and luminescence signals were read on a BioTek microplate reader (BioTek Instruments) using an integration of 0.2 cps. Data were analyzed using GraphPad Prism9 and relative luminescence units (RLU) for each antibody concentration were plotted in a scatter format of antibody concentration vs. RLU. Results were representative of two independent experiments.

[0183] The results in Figure 8 show that the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b lacked or had no ADCC activity when compared to the positive control. Similarly, representative results (not shown) for the exemplary anti-human IL-4Rα Ab1, Ab4, and Ab7 showed that the antibodies lacked or had no significant ADCC activity when compared to the positive control.

[0184] Example 5c. Complement-dependent cytotoxicity (CDC): In vitro CDC assays of the exemplified antibodies were performed using Daudi cells (ATCC, #CCL-213). All test antibodies, complement, and cells were diluted in assay medium consisting of RPMI-1640 (without phenol red) containing 0.1 mM non-essential amino acids (NEAA), 1 mM sodium pyruvate, 2 mM L-glutamine, 500 U / mL penicillin-streptomycin, and 0.1% w / v BSA. Test antibodies were initially diluted to a 3x concentration of 600 nM, then serially diluted 7 times at a 1:4 ratio. 50 μL / well of each antibody (including a CD20 positive control antibody) was dispensed in triplicate into white opaque-bottom 96-well plates (Costar, #3917). Daudi target cells were cultured at 5x10 4 Cells / well, 50 μL / well were added and incubated at 37°C for 1 hour. Human serum complement (Quidel, #A113), quickly thawed in a 37°C water bath, was then diluted 1:6 in assay medium and added to the assay plate at 50 μL / well. The plate was incubated at 37°C for 2 hours, followed by the addition of 100 μL / well of CellTiter Glo substrate (Promega, #G7571). The plate contents were mixed using a plate shaker at low speed, incubated at room temperature for 5 minutes, and the luminescence signal was read on a BioTek microplate reader (BioTek Instruments) with an integration of 0.2 cps. Data were analyzed using GraphPad Prism9, and the relative luminescence units (RLU) for each antibody concentration were plotted in a scatter format of antibody concentration vs. RLU. Results are representative of two independent experiments.

[0185] The results in Figure 9 show that the exemplary IL-4Rα AbGC conjugate of Example 1b does not induce a CDC response compared to the positive control. Similarly, representative results for the exemplary anti-human IL-4Rα Ab1, Ab4, and Ab7 (not shown) showed that the antibodies did not induce a CDC response when compared to the positive control.

[0186] Example 6. Biophysical properties of the anti-human IL-4Rα Ab1GC conjugate of Example 1b The biophysical properties of the exemplary anti-human IL-4Rα Ab1GC conjugate of Example 1b were evaluated for potential development.

[0187] Example 6a. Thermal Stability: Differential scanning calorimetry (DSC) was used to assess the stability of the exemplary antibodies against thermal denaturation. The onset melting temperatures (Tonset) and thermal melting temperatures (TM1 and TM2) of the anti-human IL-4Rα Ab1GC conjugate in PBS, pH 7.2 buffer, acetate, pH 5, and histidine, pH 6 were obtained (Table 19). Although the thermal transition temperatures for each domain were not fully characterized, the data in Table 19 and Figures 10A-C show that conjugation of the exemplary linker-payload to the four engineered cysteines on the exemplary one resulted in acceptable thermal stability.

[0188] Example 6b. Aggregation upon temperature stress: The solution stability over time of the exemplary anti-human IL-4Rα Ab1GC conjugate is evaluated at approximately 100 mg / mL in a common 5 mM histidine pH 6.0 buffer with excipients. Concentrated samples were incubated at 5° C. and 35° C. for a period of 4 weeks, respectively. After incubation, the percentage of high molecular weight (% HMW) species was analyzed using size exclusion chromatography (SEC). The results in Table 20 show that conjugation of the exemplary linker-payload to the four engineered cysteines on Ab1 results in an acceptable level of aggregation for the anti-human IL-4Rα Ab1GC conjugate over a period of 4 weeks at 35° C.

[0189] [Table 25]

[0190] [Table 26]

[0191] Example 7. In vivo function of the anti-human IL-4Rα Ab1GC conjugate of Example 1b In vivo efficacy in a fully humanized mouse model of type IV hypersensitivity: The in vivo activity of anti-human IL-4Rα Ab1 GC-conjugated anti-human IL-4Rα Ab1 was determined using a humanized mouse model of contact hypersensitivity.

[0192] Immunodeficient NOG mice (huNOG-EXL, Taconic), which express human GM-CSF and human IL-3 to support myeloid lineage development, were transplanted at 6 weeks of age with human CD34+ hematopoietic stem cells isolated from human umbilical cord blood. 20–24 weeks after stem cell administration, mice were assessed for sufficient human CD45 engraftment (>25% in blood) and subjected to an oxazolone-induced contact hypersensitivity protocol. On day 0, mice grouped by weight were administered either anti-human IL-4Rα Ab1 GC conjugate (n=8), anti-human IL-4Rα Ab1 (n=8), or control human IgG4P antibody (n=8) at 10 mg / kg subcutaneously (SC). GC alone (n=6) was administered at 0.15 mg / kg SC 24 hours prior to sensitization and each challenge. On day 1, mice were anesthetized with 5% isoflurane, their abdomens were shaved, and 100 μL of 3% oxazolone in ethanol was applied to the shaved area. On day 6, mice were dosed again with the same dose, anesthetized, and then challenged with 2% oxazolone in ethanol in both ears (10 μL / side / ear) 24 hours after dosing. The dose-challenge paradigm was repeated weekly for a total of three challenges. Inflammatory responses were determined by the difference in ear thickness before and 24 hours after each challenge using Miltenyi Biotec electronic calipers. P values ​​between groups were calculated by one-way ANOVA followed by Tukey's post-hoc test and were considered significant if <0.05 (GraphPad Prism).

[0193] The results in Table 21 show that anti-human IL-4Rα Ab1GC conjugate Example 1b was able to significantly inhibit the in vivo inflammatory response to hapten-induced contact hypersensitivity compared to all other treatments after challenges 2 and 3. Compared to the isotype control, the IL-4Rα Ab1GC conjugate reduced inflammation by 80% and 78% for challenges 2 and 3, respectively. In addition, Ab1 only significantly inhibited inflammation after challenge 2 compared to the isotype (40% reduction), but there was a trend toward activity with unconjugated Ab1. Furthermore, GC treatment using a dose and paradigm equivalent to the Ab1GC conjugate was ineffective in the model indicating that the in vivo activity was due to the Ab1GC conjugate. These results show that the anti-human IL-4Rα Ab1GC conjugate effectively delivered glucocorticoids to inflamed tissues and significantly abrogated the biological effects associated with type IV hypersensitivity reactions in a humanized mouse model, indicating that this anti-inflammatory response can be induced in human subjects.

[0194] [Table 27] * p<0.05 vs. isotype; ANOVA Tukey; ^p<0.01 vs. all; ANOVA Tukey The present invention includes the following embodiments. [Embodiment 1] formula: [ka] (wherein Ab is an antibody that binds to human IL-4Rα; During the ceremony, [ka] and n is 1 to 5. [Embodiment 2] The Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; said HCDR1 comprising SEQ ID NO: 1, 42, or 19; said HCDR2 comprising SEQ ID NO: 2 or 20, said HCDR3 comprises SEQ ID NO:3, said LCDR1 comprising SEQ ID NO: 4 or 22; said LCDR2 comprising SEQ ID NO:5, 2. The conjugate of embodiment 1, wherein said LCDR3 comprises SEQ ID NO: 6 or 24. [Embodiment 3]

change

change

change

change

change

change

change

change

[0195] Sequence Listing Ab1 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 9 HC for Ab1 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPCVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVKFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:11 HC DNA for Ab1 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab2 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO:50 HC for Ab2 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPCVFPLAPCSRSTSGSTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVKFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:51 HC DNA for Ab2 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab3 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 37 HC for Ab3 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:38 HC DNA for Ab3 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab4 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 31 HC for Ab4 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPCVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:32 HC DNA for Ab4 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab5 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 35 HC for Ab5 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVKFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 36 HC DNA for Ab5 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab6 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 33 HC for Ab6 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:34 HC DNA for Ab6 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab7 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 13 HC for Ab7 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLV TVSSASTKGPCVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:14 HC DNA for Ab7 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab8 SEQ ID NO: 1 HCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 VASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 4 LCDR1 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 RASQDISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 7 VH for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO:8 VL for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO:52 HC for Ab8 QVQLVESGGGLVQPGGSLRLSCVASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLV TVSSASTKGPCVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAAPIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 10 LC for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:53 HC DNA for Ab8 SEQ ID NO:12 LC DNA for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, and Ab8 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab9 SEQ ID NO: 42 HCDR1 (North) for Ab9 AASGFTFSHSSMN SEQ ID NO: 2 HCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 YISRATGAVY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 22 LCDR1 (North) for Ab9 and Ab10 RASQGISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO:6 LCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, and Ab9 LQWSSYPRT SEQ ID NO: 44 VH for Ab9 QVQLVESGGGLVQPGGSLRLSCAASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO: 45 VL for Ab9 DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK SEQ ID NO: 46 HC for Ab9 QVQLVESGGGLVQPGGSLRLSCAASGFTFSHSSMNWVRQAPGKGLEWVSYISRATGAVYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPCVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDICVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 47 LC for Ab9 DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQWSSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HC DNA for SEQ ID NO: 48 SEQ ID NO: 49 LC DNA for Ab9 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTGGTCCAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC Ab10 SEQ ID NO: 19 HCDR1 (North) for Ab10 AASGFTFSISSMN SEQ ID NO:20 HCDR2 (North) for Ab10 YISRATGAIY SEQ ID NO: 3 HCDR3 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 AREPVFDY SEQ ID NO: 22 LCDR1 (North) for Ab9 and Ab10 RASQGISNYLA SEQ ID NO: 5 LCDR2 (North) for Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, and Ab10 YAASSLQS SEQ ID NO: 24 LCDR3 (North) for Ab10 LQHNSYPRT SEQ ID NO: 25 VH for Ab10 QVQLVESGGGLVQPGGSLRLSCAASGFTFSISSMNWVRQAPGKGLEWVSYISRATGAIYYADSVKGRFTISRNNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTLVTVSS SEQ ID NO: 26 VL for Ab10 DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK SEQ ID NO:27 HC for Ab10 QVQLVESGGGLVQPGGSLRLSCAASGFTFSISSMNWVRQAPGKGLEWVSYISRATGAIYYADSVKGRFTISRNNAKNSLYLQMNSLRDEDTAVYYCAREPVFDYWGQGTL VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO:28 LC for Ab10 DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPTRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:29 HC DNA for Ab10 SEQ ID NO: 30 LC DNA for Ab10 GACATCCAGATGACCCAGTCTCCATCTGCCATGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAGGGAAAGTCCCTACGCGCCTGATCTATGCTGCATCCAGTT TGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCATAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGAACTGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCCGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC SEQ ID NO: 15 Human IL-4Rα extracellular domain MKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQH SEQ ID NO:16 Cynomolgus IL-4Rα extracellular domain MKVLQEPTCVSDYMSISTCEWKMGGPTNCSAELRLLYQLVFQSSETHTCVPENNGGVGCVCHLLMDDVVSMDNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTVLLTWSNPYPPDNYLYNDLTYAVNIWSENDPAYSRIHNVTYLKPTLRIPASTLKSGISYRARVRAWAQHYNTTWSEWSPSTKWYNSYREPFEQR SEQ ID NO:17 Human IL-4 MGLTSQLLPPLFFLLACAGNFVHGHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSS SEQ ID NO:18 Human IL-13 MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN SEQ ID NO: 39 Human IL-4Rα MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQ CYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFL DLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPE KCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS SEQ ID NO: 40 Cynomolgus IL-4Rα MGWLCSGLLFPVSCLVLLQVASSGCSCVSPGSMKVLQEPTCVSDYMSISTCEWKMGGPTNCSAELRLLYQLVFQSSETHTCVPENNGGVGCVCHLLMDDVVSMDNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTVLLTWSNPYPPDNYLYNDLTYAVNIWSENDPAYSRIHNVTYLKPTLRIPASTLKSGISYRARV RAWAQHYNTTWSEWSSPSTKWYNSYREPFEQRLLWGVSAACVFILFFCLSCYFSVTKIKKEWWDQIPNPARSHLVAIIIQDAQESQWEKRSRGQEAAKCPYWKNC LTKLLPCFLEHNMKRDEDPHKAVKDLPFRGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECKEEEEVEEEKGSFCTSSESNRDDFQEGREGIVARLTES LFLDLLGGENGGFFQQDMGESCLLPPLGSTSAHVPWDEFPSAGSKEVPPWGKEQPLHQEPSPPASPTQSPDNPTCTEMPLVISSNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVDPEMPCAPQLSEPTTVAPAEPETWEQILRRNVLQHGAAAAPASAPTSGYREFVHAVQQGGIQASAVAGLGPPGEAGYKAFSSLLASSAVSP GECGFGASSGEEGYKPFQDLTPGCPGDPAPVPVPLFTFGLDREPPHSPQSSHLPSNSPEHLALEPGEKVEDMQKPPLPPEQATDPLGDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQAPVVASPCCGCCCGDRSSPPTTPLRAPDPSLGGVPLEASLCPASLAPSGISEKSKSSLSFHPAPGSAQSSSQTPQIVNFVSVGPTCMRVS SEQ ID NO: 41 Human CD23 MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERAARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS

Claims

1. formula: 【Chemistry 1】 (wherein Ab is an antibody that binds to human IL-4Rα; During the ceremony, 【Chemistry 2】 and n is 1 to 5.

2. The Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; (i) said HCDR1 comprising SEQ ID NO:1; said HCDR2 comprising SEQ ID NO:2; said HCDR3 comprising SEQ ID NO:3; said LCDR1 comprising SEQ ID NO:4; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO:6; or (ii) said HCDR1 comprising SEQ ID NO: 42; said HCDR2 comprising SEQ ID NO:2; said HCDR3 comprising SEQ ID NO:3; the LCDR1 comprises SEQ ID NO:22; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO:6; or (iii) said HCDR1 comprising SEQ ID NO: 19; said HCDR2 comprising SEQ ID NO: 20; said HCDR3 comprising SEQ ID NO:3; the LCDR1 comprises SEQ ID NO:22; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO: 24; The conjugate of claim 1. 【Request 3】 【Chemistry 3】 The conjugate of claim 1 , 【Request 4】 【Chemical 4】 The conjugate of claim 1 , 【Request 5】 【Chemistry 5】 The conjugate of claim 1 or 3, 【Request 6】 【Chemical 6】 The conjugate of claim 1 or 4, 【Request 7】 【Chemical 7】 The conjugate of claim 1 or 3, 【Request 8】 【Chemical 8】 The conjugate of claim 1 or 3, 【Request 9】 【Chemical 9】 The conjugate of claim 1 or 4,

10. 【Chemical 10】 The conjugate of claim 1 or 4,

11. The Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; said HCDR1 comprising SEQ ID NO:1; said HCDR2 comprising SEQ ID NO:2; said HCDR3 comprising SEQ ID NO:3; said LCDR1 comprising SEQ ID NO:4; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO:6; The conjugate of claim 1.

12. The conjugate of claim 11, wherein the VH comprises SEQ ID NO:7 and the VL comprises SEQ ID NO:

8.

13. The Ab is i. a heavy chain (HC) comprising SEQ ID NO: 9 and a light chain (LC) comprising SEQ ID NO: 10; ii. a heavy chain (HC) comprising SEQ ID NO:50 and a light chain (LC) comprising SEQ ID NO:10; iii. a heavy chain (HC) comprising SEQ ID NO: 37 and a light chain (LC) comprising SEQ ID NO: 10; iv. a heavy chain (HC) comprising SEQ ID NO: 31 and a light chain (LC) comprising SEQ ID NO: 10; v. a heavy chain (HC) comprising SEQ ID NO: 35 and a light chain (LC) comprising SEQ ID NO: 10; vi. a heavy chain (HC) comprising SEQ ID NO: 33 and a light chain (LC) comprising SEQ ID NO: 10; vii. a heavy chain (HC) comprising SEQ ID NO: 13 and a light chain (LC) comprising SEQ ID NO: 10, or viii. A heavy chain (HC) comprising SEQ ID NO: 52 and a light chain (LC) comprising SEQ ID NO: 10; The conjugate of claim 11.

14. The Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; said HCDR1 comprising SEQ ID NO: 42; said HCDR2 comprising SEQ ID NO:2; said HCDR3 comprising SEQ ID NO:3; the LCDR1 comprises SEQ ID NO:22; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO:6; The conjugate of claim 1.

15. The conjugate of claim 14, wherein the VH comprises SEQ ID NO: 44 and the VL comprises SEQ ID NO:

45.

16. The conjugate of claim 14, wherein the Ab comprises a heavy chain (HC) comprising SEQ ID NO:46 and a light chain (LC) comprising SEQ ID NO:

47.

17. The Ab comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3; said HCDR1 comprising SEQ ID NO: 19; said HCDR2 comprising SEQ ID NO: 20; said HCDR3 comprising SEQ ID NO:3; the LCDR1 comprises SEQ ID NO:22; the LCDR2 comprises SEQ ID NO:5; the LCDR3 comprises SEQ ID NO: 24; The conjugate of claim 1.

18. 18. The conjugate of claim 17, wherein the VH comprises SEQ ID NO:25 and the VL comprises SEQ ID NO:

26.

19. 18. The conjugate of claim 17, wherein the Ab comprises a heavy chain (HC) comprising SEQ ID NO:27 and a light chain (LC) comprising SEQ ID NO:

28.

20. The Ab comprises a heavy chain and a light chain, the heavy chain comprising: A cysteine ​​at amino acid residue 124 (EU numbering), a cysteine ​​at amino acid residue 378 (EU numbering), or a cysteine ​​at amino acid residue 124 (EU numbering) and a cysteine ​​at amino acid residue 378 (EU numbering), The conjugate of claim 1.

21. 2. The conjugate of claim 1, wherein the Ab comprises a heavy chain (HC) and a light chain (LC), and the HC is a human IgG4 isotype.

22. 2. The conjugate of claim 1, wherein the Ab comprises a heavy chain (HC) and a light chain (LC), the HC being of human IgG1 isotype.

23. The conjugate of claim 1, wherein n is 2 to 5.

24. The conjugate of claim 1, wherein n is 3 to 5.

25. The conjugate of claim 1, wherein n is 3 to 4.

26. The conjugate of claim 1 , wherein n is about 4.

27. The conjugate of claim 1 , wherein n is about 3.

28. The conjugate of claim 1 , wherein n is about 2.

29. A pharmaceutical composition comprising the conjugate of claim 1 or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers, diluents, or excipients.

30. 30. A medicament for treating an inflammatory disease in a subject in need thereof, comprising the conjugate of claim 1 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition of claim 29.

31. The method of claim 30, wherein the inflammatory disease is a type 2 inflammatory disease.

32. 32. The method of claim 31, wherein the type 2 inflammatory disease is selected from atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic rhinosinusitis (CRS), allergic disease, chronic obstructive pulmonary disease (COPD), or chronic spontaneous urticaria (CSU).

33. The method of claim 32, wherein the type 2 inflammatory disease is atopic dermatitis.

34. 30. A pharmaceutical composition according to claim 29 for use in the treatment of an inflammatory disease.

35. 35. The pharmaceutical composition of claim 34, wherein the inflammatory disease is a type 2 inflammatory disease.

36. 36. The pharmaceutical composition of claim 35, wherein the type 2 inflammatory disease is selected from atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic rhinosinusitis (CRS), allergic disease, chronic obstructive pulmonary disease (COPD), or chronic spontaneous urticaria (CSU).

37. The pharmaceutical composition of claim 36, wherein the type 2 inflammatory disease is atopic dermatitis.

38. 30. Use of the conjugate of claim 1 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition of claim 29, in the manufacture of a medicament for the treatment of an inflammatory disease.

39. 39. The use according to claim 38, wherein the inflammatory disease is a type 2 inflammatory disease.

40. 40. The use of claim 39, wherein the type 2 inflammatory disease is selected from atopic dermatitis, eosinophilic esophagitis, nasal polyposis, asthma, chronic rhinosinusitis (CRS), allergic diseases, chronic obstructive pulmonary disease (COPD), or chronic spontaneous urticaria (CSU).

41. 41. The use according to claim 40, wherein the type 2 inflammatory disease is atopic dermatitis.

42. The conjugate of claim 1, wherein the Ab neutralizes human IL-4Rα.

43. The conjugate of claim 1, wherein the Ab inhibits binding of human IL-4 to human IL-4Rα.

44. The conjugate of claim 1, wherein the Ab inhibits binding of human IL-13 to human IL-4Rα.

45. The conjugate of claim 1 , wherein the Ab is an internalizing antibody.

46. A method of producing a conjugate, the conjugate comprising the conjugate of claim 1.

47. (a) reducing the anti-human IL-4Rα antibody with a reducing agent to produce a reduced anti-human IL-4R antibody, wherein the anti-human IL-4Rα antibody contains one or more engineered cysteine ​​residues; (b) oxidizing the reduced anti-human IL-4Rα antibody with an oxidizing agent to produce an oxidized anti-human IL-4R antibody; (c) reacting the oxidized anti-human IL-4R antibody with the compound of the formula 【Chemistry 11】 to produce the conjugate.

47. The method of claim 46.

48. 48. The method of claim 47, wherein the reducing agent is dithiothreitol and the oxidizing agent is dehydroascorbic acid.

Citation Information

Patent Citations

  • Glucocorticoid receptor agonists and immunoconjugates thereof

    JP2019524645A

  • Antibodies binding il4r and uses thereof

    WO2021170020A1